[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 765
1. Sonoda Y, Matsumoto K, Kakuto Y, Nishino Y, Kumabe T, Tominaga T, Katakura R: Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy. Acta Neurochir (Wien); 2007 Nov;149(11):1183-9; discussion 1189
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy.
  • OBJECT: To assess whether nimustine (ACNU), a drug that can cross the blood brain barrier, combined with radiotherapy, improved the survival of patients with primary central nervous system lymphoma (PCNSL).
  • By multivariate analysis, age (<60 vs. > or =60 years) was the only statistically significant prognostic factor; the WBRT dose, sex, and number of tumors were not significant prognostic factors in this study.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Cranial Irradiation. Infusions, Intra-Arterial. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Nimustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712511.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine
  •  go-up   go-down


2. Raparia K, Chang CC, Chévez-Barrios P: Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med; 2009 Aug;133(8):1233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven patients had central nervous system involvement and 6 patients had systemic involvement.
  • The cases included 9 primary diffuse large B-cell lymphomas of the CNS type; 2 diffuse large B-cell lymphomas, not otherwise specified; 1 extranodal, low-grade, marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT); 1 precursor B-lymphoblastic lymphoma; and 3 peripheral T-cell lymphomas, not otherwise specified.
  • [MeSH-major] Eye Neoplasms / diagnosis. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Vitrectomy / methods. Vitreous Body / pathology
  • [MeSH-minor] Adult. Aged. Cytodiagnosis / methods. Female. Flow Cytometry. Humans. Lymphoma, B-Cell, Marginal Zone / classification. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Retrospective Studies. Survival Rate. Texas / epidemiology. World Health Organization. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653716.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T: High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant; 2006 Sep;38(6):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
  • The optimum treatment of primary CNS lymphoma (PCNSL) is not yet determined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Middle Aged. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951691.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Jalali R, Srinivas C, Nadkarni TD, Rajasekharan P: Suprasellar haemangiopericytoma--challenges in diagnosis and treatment. Acta Neurochir (Wien); 2008 Jan;150(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytomas of central nervous system (CNS) were first defined as a separate entity in 1942.
  • Previously they were either considered to be a histological variant of an angioblastic meningioma or a distinctive mesenchymal neoplasm.
  • [MeSH-major] Central Nervous System Cysts / diagnosis. Central Nervous System Cysts / therapy. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Sella Turcica
  • [MeSH-minor] Adult. Craniotomy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm, Residual. Pituitary Neoplasms / diagnosis. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176777.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 18
  •  go-up   go-down


5. Muñoz-Mármol AM, Mola G, Ruiz-Larroya T, Fernández-Vasalo A, Vela E, Mate JL, Ariza A: Rarity of JC virus DNA sequences and early proteins in human gliomas and medulloblastomas: the controversial role of JC virus in human neurooncogenesis. Neuropathol Appl Neurobiol; 2006 Apr;32(2):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, JCV genomic DNA and early viral protein T-antigen have been detected in various types of human central nervous system (CNS) neoplasms.
  • To further explore this association we have studied paraffin-embedded brain biopsy tissue from 60 neoplasms (55 gliomas and five medulloblastomas) and 15 reactive gliosis cases for the presence of JCV DNA sequences and proteins.
  • Five cases (three neoplasms and two reactive gliosis instances) showed low viral DNA levels when PCR-tested for VP3 or large T, while no case was immunoreactive for any of the two antibodies used.
  • Additionally, IHC with both antibodies was applied to a tissue micro-array including 109 CNS tumours and 21 reactive gliosis samples.
  • [MeSH-major] Brain Neoplasms / virology. DNA, Viral / isolation & purification. Glioma / virology. JC Virus / genetics. Medulloblastoma / virology
  • [MeSH-minor] Adult. Animals. Antigens, Viral, Tumor / isolation & purification. Cell Transformation, Neoplastic. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599942.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  •  go-up   go-down


6. Kadan-Lottick NS, Zeltzer LK, Liu Q, Yasui Y, Ellenberg L, Gioia G, Robison LL, Krull KR: Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst; 2010 Jun 16;102(12):881-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.
  • BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system (CNS) childhood cancers, overall and compared with a sibling cohort, and to identify factors associated with worse functioning.
  • METHODS In a retrospective cohort study, 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency, emotional regulation, organization, and memory.
  • Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression.
  • RESULTS Non-CNS cancer survivors had similar or slightly worse (<0.5 standard deviation) mean test scores for all four subscales than siblings.
  • CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1207-13 [11309635.001]
  • [Cites] Psychosomatics. 2001 May-Jun;42(3):241-6 [11351113.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1539-45 [11402112.001]
  • [Cites] Child Neuropsychol. 2000 Sep;6(3):235-8 [11419452.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Med Pediatr Oncol. 2002 May;38(5):320-8 [11979456.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] Pediatrics. 1985 Apr;75(4):745-53 [3838584.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):315-20 [3422262.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):74-86 [2496615.001]
  • [Cites] Dev Med Child Neurol. 1990 Mar;32(3):238-48 [2311827.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Pediatr. 1992 Dec;121(6):885-9 [1447650.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] J Pediatr Psychol. 2005 Jan-Feb;30(1):65-78 [15610986.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):281-90 [15806539.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1742-5 [17148777.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4914-21 [17971588.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):e1229-36 [17974716.001]
  • [Cites] Neuropsychol Rev. 2008 Jun;18(2):121-31 [18415683.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3025-30 [18565888.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):159-64 [18680151.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Jan;15(1):31-41 [19128526.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2308-18 [19364948.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2626-35 [19815636.001]
  • [Cites] Neuropsychology. 2009 Nov;23(6):705-17 [19899829.001]
  • [Cites] Eur J Pharmacol. 2010 Jan 10;626(1):83-6 [19835870.001]
  • [CommentIn] J Natl Cancer Inst. 2011 Apr 6;103(7):607; author reply 607-9 [21350219.001]
  • (PMID = 20458059.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024138; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2886093
  •  go-up   go-down


7. Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A: CNS relapse in acute promyeloctyic leukemia. J Clin Oncol; 2010 Aug 20;28(24):e409-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS relapse in acute promyeloctyic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / therapy. Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Arsenicals / administration & dosage. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Cranial Irradiation. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. Idarubicin / administration & dosage. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Nuclear Proteins / genetics. Oxides / administration & dosage. Receptors, Retinoic Acid / genetics. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Translocation, Genetic. Transplantation, Autologous. Treatment Outcome. Tretinoin / administration & dosage. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Nuclear Proteins; 0 / Oxides; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 04079A1RDZ / Cytarabine; 143220-95-5 / PML protein, human; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; S7V92P67HO / arsenic trioxide; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


8. Batoroev IuK: [Cytomorphological diagnosis in the primary central nervous system lymphoma]. Klin Lab Diagn; 2010 Jan;(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphological diagnosis in the primary central nervous system lymphoma].
  • The paper provides a retrospective analysis of cases of the cytological diagnosis of the rare abnormality--primary central nervous system (CNS) lymphomas.
  • The capabilities, advantages, and disadvantages of diagnosis of both cytological and histological diagnosis of CNS lymphomas are estimated.
  • [MeSH-major] Brain Neoplasms / diagnosis. Lymphoma / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult


9. Klabusay M, Pevná M, Kissová J, Doubek M, Heidekerová M, Mayer J, Vorlícek J: [Rare diagnosis of CD4+56+ leukemia from dendritic cells type DC2]. Cas Lek Cesk; 2008;147(10):511-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4+56+ hematodermic neoplasm or leukemia from early plasmocytoid dendritic cells type DC2 was recognized by WHO-EORTC classification of cutaneous lymphomas as a separate entity related to the plasmacytoid precursor dendritic cell (pDC).
  • However, this aggressive disease requires radical approach with intensive chemotherapy regimens, prophylaxis of CNS involvement and early indication of allogeneic bone marrow transplantation.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / analysis. Dendritic Cells / immunology. Leukemia / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177732.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  • [Number-of-references] 26
  •  go-up   go-down


10. Dalmau J, Bataller L: [Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications]. Neurologia; 2007 Oct;22(8):526-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 82 % of prospectively identified patients with non-viral limbic encephalitis at our institution had 526 antibodies against proteins of the CNS.
  • Patients with antibodies against these receptors are young women with benign-appearing cystic tumors of the ovary (mature or immature teratomas), who develop a severe and characteristic encephalitis that we report in detail.
  • Despite the severity of the disorder, patients often recover after treatment of the tumor and immunotherapy.
  • [MeSH-major] Antigens, Surface / immunology. Autoantigens / immunology. Demyelinating Autoimmune Diseases, CNS / immunology. Limbic Encephalitis / immunology. Membrane Proteins / immunology. Nerve Tissue Proteins / immunology
  • [MeSH-minor] Adolescent. Adult. Autoantibodies / immunology. Combined Modality Therapy. Female. Hippocampus / immunology. Humans. Immunotherapy. Models, Anatomic. Neuropil / immunology. Ovarian Neoplasms / complications. Ovarian Neoplasms / immunology. Potassium Channels / immunology. Receptors, N-Methyl-D-Aspartate / immunology. Retrospective Studies

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000762.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Autoantibodies; 0 / Autoantigens; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Potassium Channels; 0 / Receptors, N-Methyl-D-Aspartate
  • [Number-of-references] 55
  •  go-up   go-down


11. Sezgin C, Gokmen E, Esassolak M, Ozdemir N, Goker E: Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Med Oncol; 2007;24(2):155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for central nervous system metastasis in patients with metastatic breast cancer.
  • AIMS: Patients with metastatic breast cancer (MBC) and central nervous system (CNS) involvement have an impaired survival and quality of life.
  • In this study, we investigated the risk factors for CNS metastasis among patients with MBC.
  • METHODS: The risk factors for development of CNS metastasis were analyzed in 154 patients with MBC.
  • RESULTS: Median OS was significantly poorer for patients with CNS metastasis as compared with patients with no CNS metastasis (OS, 23 mo vs 30 mo, respectively;p = 0.03).
  • Ki-67 and p53 overexpressions by IHC, and lung metastasis as the first site of relapse, were associated with a higher risk of developing CNS metastasis in the univariate analysis (p <or= 0.05).
  • The presence of lung metastasis (odds ratio [OR]= 2.82, 95% confidence interval [CI]: 1.13-7.00,p = 0.02) and p53 overexpression (OR = 2.44, 95% CI: 0.99-6.00,p = 0.05) were the two predictive factors associated with occurrence of CNS metastasis in the multivariate analysis.
  • CONCLUSIONS: In this study, the presences of lung metastasis as the first site of relapse and p53 overexpression were predictive for the occurrence of CNS metastasis in patients with MBC.
  • Life expectancy of patients with CNS metastasis is significantly shorter than those without CNS metastasis.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Predictive Value of Tests. Prevalence. Prognosis. Registries. Risk Factors. Survival Analysis. Tumor Suppressor Protein p53 / analysis


12. Jarrell ST, Vortmeyer AO, Linehan WM, Oldfield EH, Lonser RR: Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg; 2006 Aug;105(2):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Patients with hereditary cancer syndromes may be at increased risk for the development of tumor-to-tumor metastases.
  • To gain insight into the biological nature of these lesions in the central nervous system (CNS), to determine their prevalence in a familial neoplasia syndrome, and to better define their management, the authors retrospectively examined a series of cases in which metastatic lesions developed within hemangioblastomas in patients with von Hippel-Lindau (VHL) disease.
  • METHODS: The study included all cases of VHL disease in which patients underwent resection of a CNS hemangioblastoma that contained a metastasis or were found at autopsy to have a metastasis to a hemangioblastoma between January 2002 and December 2005 at the National Institute of Neurological Disorders and Stroke (NINDS).
  • Metastasis to a CNS hemangioblastoma was found in six resected tumors (8% of all hemangioblastomas resected from patients with VHL disease at the NINDS during the study period) from six patients (five women, one man; mean age at surgery 42.5 years).
  • The primary site of metastatic disease was the kidney in five patients (renal cell carcinoma) and the pancreas in one (a pancreatic neuroendocrine tumor).
  • Two patients (including one who was also in the surgical group) were found at autopsy to have CNS metastases exclusively to spinal hemangioblastomas.
  • Emerging histopathological techniques may lead to recognition of an increasing number of cases of tumor-to-hemangioblastoma metastasis.
  • Management of cases involving tumor-to-hemangioblastoma metastases in VHL disease should be based on the histological characteristics of the primary tumor, extent of the primary disease, and completeness of the resection.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Carcinoma, Renal Cell / secondary. Cerebellar Neoplasms / secondary. Hemangioblastoma / diagnosis. Kidney Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Neuroendocrine Tumors / secondary. Pancreatic Neoplasms / diagnosis. Pheochromocytoma / secondary. Spinal Cord Neoplasms / secondary. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Brain / pathology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / diagnosis. Spinal Cord / pathology. Tomography, X-Ray Computed


13. Castle J, Sakonju A, Dalmau J, Newman-Toker DE: Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. Nat Clin Pract Neurol; 2006 Oct;2(10):566-72; quiz 573
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIAGNOSIS: Anti-Ma2 paraneoplastic encephalitis in association with metastatic testicular cancer; initially misdiagnosed as CNS Whipple's disease.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Diagnostic Errors. Encephalitis / diagnosis. Nerve Tissue Proteins / metabolism. Paraneoplastic Syndromes / diagnosis. Whipple Disease / diagnosis
  • [MeSH-minor] Adult. Brain / pathology. Brain Injuries / complications. Diagnosis, Differential. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Male. Positron-Emission Tomography. Seizures / etiology. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990830.001).
  • [ISSN] 1745-834X
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunosuppressive Agents; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Glassmann A, Molly S, Surchev L, Nazwar TA, Holst M, Hartmann W, Baader SL, Oberdick J, Pietsch T, Schilling K: Developmental expression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells. BMC Dev Biol; 2007;7:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mtss1 encodes an actin-binding protein, dysregulated in a variety of tumors, that interacts with sonic hedgehog/Gli signaling in epidermal cells.
  • In the adult CNS, Mtss1 is found exclusively in cerebellar Purkinje cells.
  • Whereas immature granule cells express a Mtss1 variant observed also in peripheral tissues and comprising exon 12, this exon is replaced by a CNS-specific exon, 12a, in more mature granule cells and in adult Purkinje cells.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Cerebellum / growth & development. Gene Expression Regulation, Developmental. Microfilament Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Cerebellar Neoplasms / pathology. Exons. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Polymerase Chain Reaction. Protein Splicing / genetics. Purkinje Cells / pathology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1996 Feb 29;379(6568):837-40 [8587609.001]
  • [Cites] Neuron. 1996 Mar;16(3):587-99 [8785056.001]
  • [Cites] Biotechniques. 1997 May;22(5):812-4 [9149852.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] Int J Dev Neurosci. 1997 Oct;15(6):749-54 [9402225.001]
  • [Cites] DNA Res. 1997 Oct 31;4(5):307-13 [9455477.001]
  • [Cites] Brain Pathol. 1998 Jan;8(1):13-8 [9458162.001]
  • [Cites] Trends Neurosci. 1998 Sep;21(9):383-90 [9735946.001]
  • [Cites] J Immunol Methods. 1998 Jun 1;215(1-2):45-58 [9744747.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):34-6 [10087920.001]
  • [Cites] Eur J Neurosci. 1999 Sep;11(9):3199-214 [10510184.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):366-77 [15617680.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):240-50 [15635447.001]
  • [Cites] J Neurosci. 2005 Jan 26;25(4):869-79 [15673667.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Sep 30;105(1-2):1-10 [12399102.001]
  • [Cites] Curr Opin Cell Biol. 2003 Feb;15(1):73-81 [12517707.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8452-9 [12482861.001]
  • [Cites] Am J Hum Genet. 2003 Apr;72(4):918-30 [12621583.001]
  • [Cites] Cerebellum. 2006;5(2):77-88 [16818382.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(2):466-78 [16903854.001]
  • [Cites] Cell. 2006 Oct 6;127(1):213-26 [17018287.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):35347-58 [17003044.001]
  • [Cites] Eur J Neurosci. 2006 Nov;24(9):2491-503 [17100838.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1337-47 [17115031.001]
  • [Cites] Mol Cell Neurosci. 2006 Dec;33(4):447-58 [17049261.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] Structure. 2007 Feb;15(2):145-55 [17292833.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7624-31 [17224454.001]
  • [Cites] J Cell Biol. 2007 Mar 26;176(7):953-64 [17371834.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Curr Biol. 2007 Jun 19;17(12):R455-7 [17580073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 [10557339.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] J Mol Biol. 2000 Apr 14;297(5):1183-94 [10764582.001]
  • [Cites] Trends Neurosci. 2000 Aug;23(8):372-6 [10906801.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Biochem J. 2003 Apr 15;371(Pt 2):463-71 [12570871.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3625-30 [12824381.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):453-63 [15684034.001]
  • [Cites] J Comp Neurol. 2005 Mar 14;483(3):318-28 [15682397.001]
  • [Cites] Nat Rev Neurosci. 2005 Mar;6(3):201-14 [15711600.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2059-66 [15688017.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1153-62 [15793295.001]
  • [Cites] Cell Mol Life Sci. 2005 May;62(9):955-70 [15868099.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1699-705 [15870888.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):641-53 [16134966.001]
  • [Cites] J Neurosci. 2005 Sep 14;25(37):8578-86 [16162939.001]
  • [Cites] J Cell Sci. 2005 Nov 15;118(Pt 22):5393-403 [16280553.001]
  • [Cites] Physiology (Bethesda). 2006 Feb;21:38-47 [16443821.001]
  • [Cites] Nat Methods. 2006 Mar;3(3):175-7 [16489333.001]
  • [Cites] PLoS Biol. 2006 Apr;4(4):e86 [16602821.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):851-68 [16793553.001]
  • [Cites] Mol Biol Cell. 2006 Jul;17(7):3187-96 [16687575.001]
  • [Cites] J Neurosci. 2000 Aug 15;20(16):5899-905 [10934236.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):732-5 [11130076.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1001-4 [11163176.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Nat Neurosci. 2002 Mar;5(3):239-46 [11850630.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):58-66 [11911881.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):291-4 [12082544.001]
  • [Cites] Dev Genes Evol. 2002 Sep;212(8):403-6 [12203097.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3709-11 [12824399.001]
  • [Cites] J Neurosci Res. 2003 Aug 1;73(3):400-9 [12868073.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27981-7 [12695505.001]
  • [Cites] Cell. 2004 Jan 23;116(2):191-203 [14744431.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14929-36 [14752106.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Jun 21;150(2):177-90 [15158081.001]
  • [Cites] Nat Neurosci. 2004 Sep;7(9):923-9 [15286792.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):321-34 [15473970.001]
  • [Cites] Cancer Lett. 2004 Nov 25;215(2):209-20 [15488640.001]
  • [Cites] Protein Eng Des Sel. 2004 Jun;17(6):527-36 [15314210.001]
  • [Cites] Development. 2004 Nov;131(22):5581-90 [15496441.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):592-605 [4056828.001]
  • [Cites] Science. 1990 Apr 13;248(4952):223-6 [2109351.001]
  • [Cites] Neuroscience. 1993 Mar;53(1):121-30 [8097019.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8730-8 [7721778.001]
  • (PMID = 17925019.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Mtss1 protein, mouse; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2194783
  •  go-up   go-down


15. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. Neurology; 2009 Nov 17;73(20):1677-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies.
  • METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):211-6 [15614581.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):159-67 [19019565.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • (PMID = 19917990.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2788805
  •  go-up   go-down


16. Kuchelmeister K, Nestler U, Siekmann R, Schachenmayr W: Liponeurocytoma of the left lateral ventricle--case report and review of the literature. Clin Neuropathol; 2006 Mar-Apr;25(2):86-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this location, liponeurocytomas are very exceptional, whereas it is the typical site for classic central neurocytomas.
  • Thus, cerebellar liponeurocytoma is the most frequent neuroepithelial CNS tumor with adipose-like cells followed by ependymomas with a lipid component and supratentorial intraventricular liponeurocytoma.
  • Adipose-like cells in neurocytomas may originate by lipidization of tumor cells, metaplastic transformation of neuroectodermal cells into fat cells or by true adipocytic differentiation.
  • The present case showed also focal glial differentiation with GFAP-positivity of some tumor cells as often seen in cerebellar liponeurocytomas but much rarer in central neurocytomas.
  • Future WHO tumor classification should consider that liponeurocytomas are not restricted to the cerebellum.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lipoma / pathology. Neurocytoma / pathology
  • [MeSH-minor] Adult. Cerebellar Neoplasms / pathology. Diagnosis, Differential. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550742.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


17. Galor A, Ference SJ, Singh AD, Lee MS, Stevens GH, Perez VL, Peereboom DM: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma. Am J Ophthalmol; 2007 Jul;144(1):45-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
  • PURPOSE: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma.
  • METHODS: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic.
  • CONCLUSIONS: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Lymphoma / drug therapy. Mannitol / adverse effects. Methotrexate / adverse effects. Retinal Diseases / chemically induced
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carotid Artery, Internal. Catheterization, Peripheral. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Fluorescein Angiography. Humans. Injections, Spinal. Male. Middle Aged. Pigment Epithelium of Eye / drug effects. Pigment Epithelium of Eye / pathology. Retrospective Studies. Tomography, Optical Coherence. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2007 Dec;144(6):976; author reply 976 [18036877.001]
  • (PMID = 17601426.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 3OWL53L36A / Mannitol; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Frenkel S, Hendler K, Siegal T, Shalom E, Pe'er J: Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol; 2008 Mar;92(3):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To describe our experience in treating vitreoretinal involvement of primary central nervous system lymphoma, by intravitreal injections of methotrexate (MTX).
  • Six patients were initially diagnosed as having a non-responsive uveitis, and 16 with either CNS or systemic lymphoma with later involvement of the eye.
  • Four patients had systemic lymphoma; one of them was found to have CNS lymphoma after the ocular involvement.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Eye Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Clinical Protocols. Drug Administration Schedule. Drug Evaluation. Female. Follow-Up Studies. Humans. Injections. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / physiopathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / physiopathology. Male. Middle Aged. Treatment Outcome. Visual Acuity / drug effects. Vitrectomy. Vitreous Body

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303160.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Kim DS, Na DG, Kim KH, Kim JH, Kim E, Yun BL, Chang KH: Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology; 2009 May;251(2):467-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
  • PURPOSE: To determine retrospectively whether unenhanced computed tomographic (CT) images of the brain have added value in distinguishing tumefactive demyelinating lesions (TDLs) from primary glioma or central nervous system (CNS) lymphoma, compared with conventional contrast material-enhanced magnetic resonance (MR) images only.
  • Unenhanced CT and MR images in 15 patients with TDLs (seven women, eight men; mean age, 42 years; range, 27-57 years) and 48 patients with primary brain tumor (27 women, 21 men; mean age, 48 years; range, 19-70 years; 10 lymphomas, 38 gliomas) were retrospectively reviewed.
  • The diagnostic accuracy of MR imaging for differentiating TDLs from tumors was compared with that of MR imaging plus CT.
  • RESULTS: The following MR imaging features were found more frequently in patients with TDL than in those with brain tumor: incomplete rim enhancement, mixed T2-weighted iso- and hyperintensity of enhanced regions, absence of a mass effect, and absence of cortical involvement (all P values < .05).
  • CT hypoattenuation of MR enhanced regions was observed in 14 (93%) of 15 patients with TDL but in only two (4%) of 48 patients with tumor.
  • The CT attenuation of MR enhanced regions was significantly lower for patients with TDL than for those with tumor (P < .001).
  • CONCLUSION: Unenhanced CT plus MR imaging was more accurate for distinguishing TDLs from glioma or CNS lymphoma than contrast-enhanced MR imaging alone.
  • [MeSH-major] Brain Neoplasms / diagnosis. Demyelinating Diseases / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Contrast Media. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult


20. Kosmas C, Tsakonas G, Mylonakis N: Treatment strategies in CNS metastases. Expert Opin Pharmacother; 2008 Aug;9(12):2087-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategies in CNS metastases.
  • BACKGROUND: CNS metastases constitute the most common brain malignancy in adults and, therefore, represent a challenging issue in cancer treatment.
  • METHODS: Therapeutic approaches in treating CNS metastases include surgery, radiotherapy and systemic chemotherapy, and are reviewed through a critical evaluation of published recent literature; however, in the majority of most common malignancies spreading to the CNS, treatment remains largely palliative and rarely curative, as is the case for other metastastic sites.
  • CONCLUSIONS: It is anticipated that a multidisciplinary approach with rapid integration of new treatment strategies is required for the treatment of patients developing CNS metastases, ultimately aiming to prolong survival, preserve neurologic function and improve quality of life.
  • [MeSH-major] Brain Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Breast Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Lung Neoplasms / pathology. Male. Melanoma / pathology. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18671464.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 81
  •  go-up   go-down


21. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J: High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol; 2006 Aug 20;24(24):3865-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
  • PURPOSE: To improve survival and reduce toxicity in primary CNS lymphoma (PCNSL) treatment, we conducted a multicenter phase II study with early high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) followed by hyperfractionated whole-brain radiotherapy (WBRT) for newly diagnosed PCNSL patients younger than 65 years of age.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Hematopoietic Stem Cell Transplantation. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Cranial Irradiation. Cytarabine / administration & dosage. Dose Fractionation. Drug Administration Schedule. Female. Germany. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Thiotepa / administration & dosage. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 905Z5W3GKH / Thiotepa; U68WG3173Y / Carmustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, Ohkawa M: Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging; 2007 Jan;34(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.
  • PURPOSE: The purpose of this study was to investigate the accumulation of FDG in immunocompetent patients with primary central nervous system (CNS) lymphoma using qualitative and quantitative PET images and to compare baseline with follow-up PET after therapy.
  • METHODS: Twelve immunocompetent patients with CNS lymphoma were examined.
  • RESULTS: A total of 12 lesions were identified in ten patients with newly diagnosed CNS lymphoma.
  • CONCLUSION: Kinetic analysis, especially with respect to k (3), using dynamic FDG PET might be helpful for diagnosis of CNS lymphoma and for monitoring therapeutic assessment.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Image Interpretation, Computer-Assisted / methods. Lymphoma / diagnosis. Lymphoma / metabolism
  • [MeSH-minor] Adult. Computer Simulation. Female. Humans. Immunocompetence / immunology. Kinetics. Male. Middle Aged. Models, Biological. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jun;30(6):377-81 [1700316.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):500-9 [11937594.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):164-8 [16220304.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] FEBS Lett. 1987 May 25;216(1):128-32 [3582661.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] J Neurooncol. 1992 Feb;12 (2):159-65 [1560262.001]
  • [Cites] J Cereb Blood Flow Metab. 1985 Jun;5(2):163-78 [3872872.001]
  • [Cites] J Neurochem. 1977 May;28(5):897-916 [864466.001]
  • [Cites] Radiographics. 1994 Jan;14 (1):101-10 [8128041.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Clin Positron Imaging. 1998 Dec;1(1):15-30 [14516605.001]
  • [Cites] Radiology. 1995 Oct;197(1):221-6 [7568827.001]
  • [Cites] Radiology. 1994 Jan;190(1):111-6 [8259386.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] Nucl Med Biol. 2002 May;29(4):443-53 [12031879.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1485-90 [1714497.001]
  • [Cites] J Nucl Med. 1992 Apr;33(4):532-6 [1552337.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1384-6 [9293793.001]
  • [Cites] J Nucl Med. 1997 Jul;38(7):1027-9 [9225785.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1528-35 [15347720.001]
  • [Cites] Blood. 1998 Jun 15;91(12 ):4464-71 [9616140.001]
  • [Cites] Mol Imaging Biol. 2003 Jan-Feb;5(1):32-41 [14499160.001]
  • [Cites] J Nucl Med. 1997 Oct;38(10 ):1575-83 [9379195.001]
  • [Cites] Eur J Nucl Med. 1998 Sep;25(9):1261-9 [9724375.001]
  • [Cites] Ann Neurol. 1979 Nov;6(5):371-88 [117743.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1298-312 [12091059.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • (PMID = 16896670.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Policarpio-Nicolas ML, Le BH, Mandell JW, Lopes MB: Granular cell tumor of the neurohypophysis: report of a case with intraoperative cytologic diagnosis. Diagn Cytopathol; 2008 Jan;36(1):58-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the neurohypophysis: report of a case with intraoperative cytologic diagnosis.
  • Cytological techniques including touch and smear preparations are very useful diagnostic modality in the evaluation of central nervous system (CNS) lesions and, in many instances, may be effectively used as the sole modality of tissue preparation for intraoperative consultation.
  • Cytologic preparations offer many advantages over frozen sections for CNS specimens.
  • We describe the cytologic diagnosis of a granular cell tumor (GCT) of the neurohypophysis in a 33-year-old male who presented with headache and blurred vision.
  • [MeSH-major] Granular Cell Tumor / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cytological Techniques. Humans. Intraoperative Period. Male

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064694.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Amirjamshidi A, Abbassioun K, Parsa K: Hiccup and neurosurgeons: a report of 4 rare dorsal medullary compressive pathologies and review of the literature. Surg Neurol; 2007 Apr;67(4):395-402; discussion 402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When encountering a case of IH, appropriate CNS imaging studies should be included in the evaluation protocol.
  • [MeSH-major] Arnold-Chiari Malformation / pathology. Brain Neoplasms / pathology. Cerebellum / blood supply. Ependymoma / pathology. Hiccup / etiology. Intracranial Aneurysm / pathology
  • [MeSH-minor] Adolescent. Adult. Humans. Male. Medulla Oblongata


25. Krasnianski M, Müller T, Stock K, Zierz S: Bruns syndrome caused by intraventricular tumor. Eur J Med Res; 2007 Dec 14;12(12):582-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bruns syndrome caused by intraventricular tumor.
  • Although the old neurological literature recognized tumors as well as neurocysticercosis as causes of the Bruns syndrome, during the last 60 years only intraventricular neurocysticercosis was reported to cause this symptom-complex.
  • The cranial MRI revealed a tumor in the third ventricle and a further tumor in the fourth ventricle, which could cause a transient obstruction of the CSF pathways.
  • This unusual observation of the Bruns syndrome in a non-parasitary disease of the CNS adds the syndrome to the differential diagnosis of paroxysmal vertigo.
  • [MeSH-major] Ataxia / diagnosis. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / diagnosis. Headache / diagnosis. Vertigo / diagnosis. Vomiting / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Syndrome

  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024268.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH: Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer; 2008 Jul 1;113(1):158-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Associations between patient and tumor characteristics, treatment modality, and survival were assessed.
  • Sex, Karnofsky performance status, tumor location, recursive partitioning analysis class, and initial treatment modality did not have an impact on survival.
  • CONCLUSIONS: Because BM from CRC are a late-stage phenomenon, the majority of patients in the current study had other systemic involvement, and survival after CNS involvement was poor.
  • Late development (>1 year after the primary tumor diagnosis) of CNS involvement may predict for poorer survival after therapy for patients with BM from CRC.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cranial Irradiation. Female. Humans. Male. Middle Aged. Prognosis. Radiosurgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18459179.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA009614-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Abdelsalam M, El-Husseiny G, Akhtar S, Khafaga Y, Al-Shabana M, AlHusaini H, El Weshi A, Rahal M, Maghfoor I: Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma. Hematol Oncol Stem Cell Ther; 2010;3(3):128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
  • BACKGROUND: Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor.
  • Patient characteristics were comparable between two groups except for higher multifocal tumor in the CMT group (92% vs. x22%, p=.029).
  • Univariate regression analysis using one-way analyses of variance (ANOVA) and multivariate Cox regression analysis for prognostic factors including age (<60 vs. >60 years), ECOG PS (0-2 vs. 3-4), extent of surgery (biopsy vs. debulking), solitary vs multifocal tumor and dose of radiation therapy (<50 Gy vs. >50 Gy) failed to identify any prognostic factor.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma / therapy. Methotrexate / therapeutic use. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Regression Analysis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890070.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


28. Moise D, Madhusoodanan S: Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr; 2006 Jan;11(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric symptoms associated with brain tumors: a clinical enigma.
  • Patients in psychiatric settings may present with medical conditions, such as brain tumors, which may or may not be associated with neurological symptoms.
  • Brain tumors may be detected in patients at their first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses.
  • Brain imaging showed the presence of a left thalamic tumor, later confirmed as glioblastoma multiforme.
  • With this we show that in some cases, brain tumors can be neurologically silent and only present atypical psychiatric symptoms.
  • [MeSH-major] Brain Neoplasms / complications. Depressive Disorder, Major / etiology. Stress Disorders, Post-Traumatic / etiology
  • [MeSH-minor] Adult. Female. Functional Laterality. Humans. Severity of Illness Index. Thalamus / surgery


29. Rousseau A, Kujas M, Bergemer-Fouquet AM, van Effenterre R, Hauw JJ: Survivin expression in ganglioglioma. J Neurooncol; 2006 Apr;77(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy.
  • These are usually well differentiated neuroepithelial tumors composed of neurons in association with neoplastic glial cells.
  • Ten lesions were low-grade neoplasms whereas 5 were high-grade tumors.
  • Two additional tumors expressed survivin upon relapse.
  • Extended lifespan in survivin expressing cells might enhance aggressive behavior in these tumors through accumulation of mutations, thereby allowing progression to malignant phenotypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ganglioglioma / metabolism. Ganglioglioma / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):173-83 [12241112.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):989-1003 [9041162.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7494-506 [15326475.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1055-9 [8847572.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2229-37 [15512811.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):360-8; discussion 368-9 [10825522.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] J Neurooncol. 2005 May;72(3):203-8 [15937641.001]
  • [Cites] Epilepsia. 1993 Jul-Aug;34(4):609-15 [8330569.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):310-4 [1476942.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2100-4 [10561264.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):59-66 [12125968.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1204-9 [11092988.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):867-73 [8246055.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):55-8 [11223561.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):557-64 [9856655.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 16292482.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Molcanyi M, Riess P, Haj-Yasein NN, Bentz K, Loehr M, Kuchta J, Zivcak J, Stenzel W, Miletic H, Hescheler J, Neugebauer E, Hampl JA, Ernestus RI, Schafer U: Developmental potential of the murine embryonic stem cells transplanted into the healthy rat brain--novel insights into tumorigenesis. Cell Physiol Biochem; 2009;24(1-2):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although engraftment of undifferentiated pluripotent embryonic stem cells (ESCs) into the injured central nervous system (CNS) may lead to targeted cell replacement of lost/damaged cells, sustained proliferative activity combined with uncontrolled differentiation of implanted cells presents a risk of tumor formation.
  • However, xenotransplantation (e.g., mouse to rat) without pre-differentiation, lead to the development of healthy neuronal cells, in absence of tumor formation, suggesting that tumor-suppressive effects of host tissue on engrafted ESCs may play a role in transplant tumorigenesis.
  • We critically investigated tumorigenesis and possible mechanisms of anticipated tumor-suppressive effect under conditions analogous to previously published studies.
  • Xenotransplantation of D-3 murine ESCs into uninjured adult rat brains lacking any preliminary inflammatory potential was found to lead to tumor formation in 5 out of 8 of animals within 2 weeks postimplantation.
  • Tumor-suppressive effects, reflected by Erdo et. al could possibly be ascribed to immunomodulatory activity of macrophages scavenging the tumorigenic fraction of the implanted cells.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Embryonic Stem Cells / transplantation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19590196.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Costello TG, Cormack JR, Mather LE, LaFerlita B, Murphy MA, Harris K: Plasma levobupivacaine concentrations following scalp block in patients undergoing awake craniotomy. Br J Anaesth; 2005 Jun;94(6):848-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no episodes in any of the 10 patients of symptoms or signs suggestive of either CNS or CVS toxicity.
  • CONCLUSIONS: This study demonstrated a relatively rapid rise of plasma levobupivacaine concentration without evidence of cardiovascular or central nervous system sequelae in a sample population of patients who may be particularly prone to perioperative seizures.
  • [MeSH-minor] Adult. Brain Neoplasms / surgery. Epilepsy / surgery. Female. Humans. Male. Middle Aged

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817709.001).
  • [ISSN] 0007-0912
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Local; A5H73K9U3W / levobupivacaine; Y8335394RO / Bupivacaine
  •  go-up   go-down


32. Seymour ZA, Panigrahy A, Finlay JL, Nelson MD Jr, Blüml S: Citrate in pediatric CNS tumors? AJNR Am J Neuroradiol; 2008 May;29(5):1006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Citrate in pediatric CNS tumors?
  • BACKGROUND AND PURPOSE: In a subset of in vivo MR spectra acquired from pediatric brain tumors, we have observed an unassigned peak.
  • The goal of this study was to determine the molecule of origin, and the prevalence and concentration of this chemical in various pediatric brain tumors.
  • MATERIALS AND METHODS: Single-voxel point-resolved spectroscopy (PRESS) spectra from 85 patients with brain tumors and 469 control subjects were analyzed.
  • CONCLUSION: MR signal consistent with citrate was observed in pediatric brain tumors and in the developing brain of infants younger than 6 months.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Citric Acid / metabolism. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Biomarkers / metabolism. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272551.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA97452-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 2968PHW8QP / Citric Acid
  •  go-up   go-down


33. Santi M, Quezado M, Ronchetti R, Rushing EJ: Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization. J Neurooncol; 2005 Mar;72(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.
  • Few studies have yielded reliable data that distinguish between ependymal neoplasms based on molecular genetic attributes.
  • The present study utilizes chromogenic in situ hybridization (CISH), a relatively recent hybridization technique, to retrospectively examine chromosome 7-copy number in pediatric and adult ependymomas.
  • Of the 27 hybridizations, polysomy of chromosome 7 was detected in 10 out of 15 (66%) adult ependymomas, and in only three out of 12 (25%) pediatric lesions.
  • The remaining tumors were diploid.
  • The authors conclude that (1) there are distinct genetic subsets of ependymoma, in particular, increases in copy number of chromosome 7 are almost exclusively found in myxopapillary ependymoma, and that (2) CISH is a rapid and sensitive method of stratifying morphological variants of ependymoma and potentially other central nervous system (CNS) tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 7 / genetics. Ependymoma / genetics. Ploidies. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Chromogenic Compounds / analysis. Humans. In Situ Hybridization / methods. Infratentorial Neoplasms / classification. Infratentorial Neoplasms / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]
  • [Cites] J Neurosurg. 1992 Jun;76(6):997-1003 [1588436.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):227-87 [14752523.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1545-51 [11706062.001]
  • [Cites] Cancer Genet Cytogenet. 1992 May;60(1):67-73 [1591709.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] Am J Clin Pathol. 1997 Aug;108(2):166-74 [9260757.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 1;130(1):79-83 [11672779.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] Mod Pathol. 2002 May;15(5):526-31 [12011257.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Sep;62(9):927-35 [14533782.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):25-33 [9525835.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2232-44 [14601094.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1411-7 [15042675.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 1;122(1):18-25 [11104027.001]
  • [Cites] Pathol Int. 2001 Oct;51(10):786-91 [11881731.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 15;136(2):121-5 [12237235.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):150-2 [8603343.001]
  • (PMID = 15803371.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down


34. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A, German Primary Central Nervous System Lymphoma Study Group: Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol; 2006 Nov;80(2):159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
  • Data on relapsed primary central nervous system lymphoma (PCNSL) are limited.
  • Forty-four of 51 evaluable patients relapsed within the CNS, 6 systemically and one both cerebrally and systemically.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Karnofsky Performance Status. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Salvage Therapy. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):339-45 [9031115.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):530-4 [10027325.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):177-83 [15638851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1157-62 [9539572.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):247-52 [11835382.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663-73 [7558957.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B113-7 [11757691.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] Eur J Haematol. 1998 Jul;61(1):59-64 [9688294.001]
  • [Cites] J Neurooncol. 1996 Dec;30(3):257-65 [8943101.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 16699873.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer; 2005 Jun 1;103(11):2344-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The central nervous system (CNS) was the initial site of disease recurrence in 7 (33%) patients (BM in 5 and LM in 2).
  • Four (57%) of the patients with disease recurrence in the CNS had lung disease under control.
  • The actuarial 5-year incidence of CNS metastases was 60%.
  • The median overall survival periods were 15 months and 23 months for patients with and without CNS metastases, respectively (P = 0.24).
  • CONCLUSIONS: The CNS was a frequent site of disease recurrence in patients with NSCLC after an initial response to gefitinib, regardless of disease control in the lungs.
  • Intrinsic resistance of metastatic clones, incomplete CNS penetrance of the drug, and longer survival are possible explanations for this high incidence.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Failure


36. Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 2006 Nov 15;119(10):2487-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of multiple genes in primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation.
  • We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR.
  • Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Epigenesis, Genetic. Gene Silencing. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic


37. Holfort SK, Lindegaard J, Isager P, Prause JU, Heegaard S: CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation. Br J Ophthalmol; 2009 May;93(5):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation.
  • AIM: To characterise uveal melanoma that has metastasised to the central nervous system (CNS).
  • All patients with malignant uveal melanoma and metastasis to the CNS were identified.
  • RESULTS: Sixteen patients with CNS metastasis were identified.
  • The majority of CNS metastases were located in the frontal and parietal lobes.
  • Five patients had exclusively metastasis to the CNS.
  • The average time from diagnosis of primary tumour to symptoms of CNS metastasis was 91 months.
  • The average time from the initial CNS symptoms to death was 20 months.
  • CONCLUSION: The proportion of uveal melanoma patients having CNS metastasis was 0.7%.
  • Eleven patients had multiple organ metastases, and the average time from the initial CNS symptoms to death was 8 months.
  • Five patients had metastasis to the CNS solely, and the average time from the initial CNS symptoms to death was 57 months.
  • [MeSH-major] Brain Neoplasms / secondary. Melanoma / secondary. Uveal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Registries. Time Factors. Young Adult


38. Sasaki M, Sugimoto K, Masuda A, Tsukune Y, Yahata Y, Komatsu N: Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy. J Neurooncol; 2010 Sep;99(2):295-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Aug 1;95(3):576-80 [12209750.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):13-21 [16173958.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1336-43 [8315431.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2306-13 [8246020.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2479-85 [10561312.001]
  • [Cites] J Neurooncol. 2009 Oct;95(1):135-139 [19381440.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:52-8 [18821433.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1364-71 [18603558.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):804-8 [1692089.001]
  • (PMID = 20151175.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


39. Ryberg M, Nielsen D, Osterlind K, Andersen PK, Skovsgaard T, Dombernowsky P: Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat; 2005 Jun;91(3):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy.
  • In order to identify factors predictive of central nervous system (CNS) metastasis, we reviewed the histories of 579 patients treated with epirubicin-based chemotherapy for metastatic breast cancer.
  • In this period, one hundred and twenty-four patients (21.4%) developed CNS metastasis.
  • Lung, liver, and lymph node metastases and oestrogen receptor negative or unknown tumor were predictive as well.
  • The risk of CNS metastasis differed considerably among risk groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Incidence. L-Lactate Dehydrogenase / analysis. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Prognosis. Prospective Studies. Receptors, Estrogen / metabolism. Risk Factors. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952055.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


40. Vasudevan V, Cheung MC, Yang R, Zhuge Y, Fischer AC, Koniaris LG, Sola JE: Pediatric solid tumors and second malignancies: characteristics and survival outcomes. J Surg Res; 2010 May 15;160(2):184-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric solid tumors and second malignancies: characteristics and survival outcomes.
  • BACKGROUND: To examine the incidence, characteristics, and outcomes for second malignancies following the diagnosis of a primary solid tumor in pediatric patients.
  • Mean age at diagnosis of the primary tumor was 7.7 y.
  • The most common primary malignancies were CNS tumors (22.5%), followed by soft tissue sarcoma (15.8%), retinoblastoma (14.1%), and bone tumors (13%).
  • Hematologic malignancies (35.5%) were the most common second malignancies noted in the cohort, followed by bone tumors (18%) and soft tissue sarcomas (15%).
  • Hematologic malignancies had a shorter latency (3.1 y) compared with solid second tumors (11.6 y).
  • For most tumor categories, development of a secondary malignancy was associated with lower 5- and 10-y survival than expected.
  • CONCLUSIONS: CNS tumors, retinoblastoma, and soft tissue sarcomas in children are the most common solid primary tumors, with an increased risk of a second malignancy.
  • Leukemia is the most common second malignancy seen in pediatric solid tumors.
  • [MeSH-major] Neoplasms / mortality. Neoplasms, Second Primary / mortality. SEER Program
  • [MeSH-minor] Adolescent. Bone Neoplasms / mortality. Central Nervous System Neoplasms / mortality. Child. Child, Preschool. Female. Follow-Up Studies. Hematologic Neoplasms / mortality. Humans. Incidence. Male. Retinoblastoma / mortality. Sarcoma / mortality. Soft Tissue Neoplasms / mortality. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19765728.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Armstrong GT, Whitton JA, Gajjar A, Kun LE, Chow EJ, Stovall M, Leisenring W, Robison LL, Sklar CA: Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer; 2009 Jun 1;115(11):2562-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.
  • To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited.
  • METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche.
  • RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9).
  • In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4).
  • CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] Pediatr Res. 2000 May;47(5):586-91 [10813581.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):854-8 [17729247.001]
  • [Cites] Klin Padiatr. 2001 Jul-Aug;213(4):239-43 [11528557.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):672-9 [11914195.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Jun;54(6):1164-8 [6804477.001]
  • [Cites] J Pediatr. 1985 Jan;106(1):156-60 [3965676.001]
  • [Cites] Horm Res. 1985;22(1-2):78-82 [4029883.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Spring;9(1):15-22 [3109271.001]
  • [Cites] Arch Dis Child. 1987 Nov;62(11):1107-12 [3479948.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):143-51 [2501681.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Sep;31(3):363-73 [2559824.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):1-5 [3152908.001]
  • [Cites] Ann Hum Biol. 1991 Mar-Apr;18(2):155-66 [2024949.001]
  • [Cites] Eur J Pediatr. 1991 Jul;150(9):630-3 [1915514.001]
  • [Cites] N Engl J Med. 1993 Jan 14;328(2):87-94 [8416438.001]
  • [Cites] Pediatr Res. 1993 Jun;33(6):577-82 [8378115.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1282-6 [8200926.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):167-71 [7749768.001]
  • [Cites] Arch Pediatr Adolesc Med. 1996 Jun;150(6):589-92 [8646307.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):598-602 [9386666.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):351-6 [9589084.001]
  • [Cites] Eur J Pediatr. 1998 Sep;157(9):703-7 [9776525.001]
  • [Cites] J Bone Miner Metab. 2005;23(6):470-5 [16261454.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1723-8 [16492690.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] Pediatrics. 2008 Feb;121 Suppl 3:S218-30 [18245514.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):605-12 [11290436.001]
  • (PMID = 19309737.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA055727-14; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA055727-14; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS113297; NLM/ PMC2746632
  •  go-up   go-down


42. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.
  • Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology
  • [MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]
  • [Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]
  • [Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]
  • [Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]
  • [Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]
  • [Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [12957360.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • (PMID = 17453149.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


43. Singh G, Fletcher O, Bell GS, McLean AE, Sander JW: Cancer mortality amongst people with epilepsy: a study of two cohorts with severe and presumed milder epilepsy. Epilepsy Res; 2009 Feb;83(2-3):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SMR for brain and CNS neoplasms was significantly elevated in the MEC; most cancer deaths in younger ages (<45 years) in this cohort were due to brain and CNS neoplasms.
  • [MeSH-major] Epilepsy / complications. Neoplasms / complications. Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Brain Neoplasms / complications. Brain Neoplasms / mortality. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101120.001).
  • [ISSN] 1872-6844
  • [Journal-full-title] Epilepsy research
  • [ISO-abbreviation] Epilepsy Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol; 2008 Apr 20;26(12):1993-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: One third of women with advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches.
  • Tumor response was assessed by magnetic resonance imaging every 8 weeks.
  • The primary end point was objective response (complete response [CR] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST).
  • Secondary end points included objective response in non-CNS sites, time to progression, overall survival, and toxicity.
  • Seven patients (18%) were progression free in both CNS and non-CNS sites at 16 weeks.
  • Exploratory analyses identified additional patients with some degree of volumetric reduction in brain tumor burden.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Nov 1;26(31):5137-8; author reply 5138-9 [18838700.001]
  • (PMID = 18421051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000046; United States / NIBIB NIH HHS / EB / R01EB000219; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / P50 CA058223; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NCRR NIH HHS / RR / M01RR00046; United States / NCI NIH HHS / CA / CA58223; United States / NCI NIH HHS / CA / CA89393; United States / NIBIB NIH HHS / EB / R01 EB000219-09; United States / NCI NIH HHS / CA / P30 CA006516
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS511902; NLM/ PMC4524351
  •  go-up   go-down


45. Peres LC, Ribeiro-Silva A: The autopsy in a tertiary teaching hospital in Brazil. Ann Clin Lab Sci; 2005;35(4):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The causes of death distributed among the ICD-10 categories were: cardiovascular diseases 21.3%, infectious diseases 19.2%, neoplasms 12.8%, perinatal conditions 10.8%, respiratory diseases 6.6%, gastrointestinal diseases 6.0%, congenital anomalies 4.7%, CNS diseases 3.8%, genitourinary diseases 1.8%, and others 13.0%.
  • [MeSH-minor] Adolescent. Adult. Brazil. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254253.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were evaluated for response every 8 weeks and remained on the study until the tumor progressed or toxicities occurred.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


47. Doyle DM, Einhorn LH: Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.
  • PURPOSE: Central nervous system (CNS) metastases are uncommon in patients with germ cell tumors, with an incidence of 2-3%.
  • CNS metastases have been managed with whole brain radiotherapy (WBRT) and concomitant cisplatin-based combination chemotherapy.
  • Our previous study did not observe serious CNS toxicity (Int J Radiat Oncol Biol Phys 1991;22:17-22).
  • We now report on 5 patients who developed delayed significant CNS toxicity.
  • PATIENTS AND METHODS: We observed 5 patients with delayed CNS toxicity.
  • Of the 5 patients, 3 had CNS metastases at diagnosis and 2 developed relapses with CNS metastases.
  • The median time from WBRT to CNS symptoms was 72 months (range, 9-228).
  • CONCLUSION: Whole brain radiotherapy is not innocuous in young patients with germ cell tumors and can cause late CNS toxicity.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Neoplasms, Germ Cell and Embryonal / radiotherapy. Radiation Injuries / complications. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / blood. Choriocarcinoma / drug therapy. Choriocarcinoma / radiotherapy. Choriocarcinoma / secondary. Chorionic Gonadotropin / blood. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / etiology. Lung Neoplasms / secondary. Male. Neoplasm Proteins / blood. Radiotherapy Dosage. Salvage Therapy / methods. Stem Cell Transplantation. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1300-2 [18374219.001]
  • (PMID = 18374223.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Kinsler VA, Chong WK, Aylett SE, Atherton DJ: Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. Br J Dermatol; 2008 Sep;159(4):907-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Congenital melanocytic naevi (CMNs) can be associated with abnormalities of the cental nervous system (CNS) and/or with melanoma.
  • Magnetic resonance imaging (MRI) of the CNS was offered on the basis of CMN phenotype.
  • RESULTS: One hundred and twenty patients (54 boys and 66 girls) who had MRI of the CNS were included in the analysis.
  • Sixty-five per cent had naevi > 20 cm projected adult size or multiple CMNs (40% > 40 cm), and 83% had satellite lesions at birth.
  • MRI and/or clinical neurological abnormalities were found in 22 patients (18%) and were significantly associated with projected adult size of the CMN (particularly > 40 cm), and independently with male gender.
  • CONCLUSIONS: This is the largest study of CNS imaging in patients with CMNs.
  • [MeSH-major] Central Nervous System Diseases / etiology. Melanoma / complications. Nevus, Pigmented / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18671780.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Chamberlain MC, Johnston SK: High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol; 2010 Jul;12(7):736-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
  • We conducted a prospective Phase II study of high-dose methotrexate (HD-MTX) and rituximab with deferred whole brain radiotherapy in patients with newly diagnosed B-cell primary central nervous system lymphoma with a primary objective of evaluating progression-free survival (PFS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Prospective Studies. Rituximab. Survival Rate / trends. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4730-5 [17947720.001]
  • [Cites] Neurology. 2008 Jan 29;70(5):401-2 [18227422.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5643-6 [15355887.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurology. 1991 Jan;41(1):95-100 [1985302.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1707-8 [10762527.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):247-52 [11835382.001]
  • [Cites] Neurology. 2002 May 28;58(10):1513-20 [12034789.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2726-31 [12860951.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Neurooncol. 1994;20(2):177-85 [7807194.001]
  • [Cites] Ann Neurol. 1995 Aug;38(2):202-9 [7654067.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2125-34 [9164227.001]
  • [Cites] Oncol Rep. 1998 Mar-Apr;5(2):521-5 [9468593.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):809-13 [15936564.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):201-5 [16193393.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Neurology. 2006 May 9;66(9):1435-8 [16682682.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3865-70 [16864853.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4570-4 [17008697.001]
  • [Cites] Neurology. 2007 Sep 11;69(11):1178-82 [17846417.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):864-7 [17325700.001]
  • (PMID = 20511181.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2940660
  •  go-up   go-down


50. Banerjee J, Pääkkö E, Harila M, Herva R, Tuominen J, Koivula A, Lanning M, Harila-Saari A: Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol; 2009 Oct;11(5):543-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cranially irradiated survivors are predisposed to the development of CNS tumors.
  • Our aim was to describe the incidence of secondary brain tumors and to define the significance of treatment-related risk factors and host characteristics in a cohort of childhood leukemia survivors.
  • Our cohort consisted of 60 consecutive cranially irradiated adult survivors of childhood leukemia treated in Oulu University Hospital (Oulu, Finland); MRI of the brain was performed on 49.
  • The sites of the tumors, their histology, and details of the leukemia treatment were determined.
  • Of the 49 patients, 11 (22%) 1-8 years of age at the time of diagnosis developed meningioma later in life, while no other brain tumors were seen.
  • [MeSH-major] Leukemia / radiotherapy. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Humans. Incidence. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Risk Factors. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):182-4 [18577989.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):218-21 [11668501.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Cancer. 2003 May 15;97(10):2588-96 [12733158.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Neurosurg. 2003 Jun;17(3):219-25 [14565516.001]
  • [Cites] J Adolesc Health. 2004 Apr;34(4):324-9 [15041002.001]
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1081-90 [7237365.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Childs Nerv Syst. 1989 Jun;5(3):135-9 [2758424.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] Neuroradiology. 1994 Nov;36(8):652-5 [7862289.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Br J Neurosurg. 1995;9(5):629-37 [8561935.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):318-22 [8707402.001]
  • [Cites] Lancet. 1997 May 10;349(9062):1369 [9149706.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] J Radiat Res. 1999 Mar;40(1):49-57 [10408177.001]
  • [Cites] Br J Ophthalmol. 1953 Dec;37(12):758-62 [13115610.001]
  • [Cites] Neurology. 2005 Jan 25;64(2):350-2 [15668439.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):617-21 [15799195.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):480-7 [17630615.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • (PMID = 19179425.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2765343
  •  go-up   go-down


51. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).
  • Among newly diagnosed tumors, thrombosis was present in 92% of GBM resections, significantly greater than other types of CNS malignancies.
  • Of tumors with thrombosis, GBMs had a higher frequency of affected vessels than AAs, DAs, AOs, ODs and MBs, but had a frequency similar to METs and PCNSLs.
  • The sensitivity of thrombosis for the diagnosis of GBM in this set of tumors was 92% and the specificity was 91%.
  • Thus, intravascular thrombosis is more frequent in GBM than other CNS malignancies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


53. Prosiegel M, Höling R, Heintze M, Wagner-Sonntag E, Wiseman K: Swallowing therapy--a prospective study on patients with neurogenic dysphagia due to unilateral paresis of the vagal nerve, Avellis' syndrome, Wallenberg's syndrome, posterior fossa tumours and cerebellar hemorrhage. Acta Neurochir Suppl; 2005;93:35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent etiology was stroke (48%), followed by CNS tumours (13%).
  • Based on our results it can be assumed that in these patients pressure is exerted on both dorsomedial central pattern generators (DMCPGs) for swallowing in a posterior-anterior direction.
  • [MeSH-major] Brain Hemorrhage, Traumatic / epidemiology. Deglutition Disorders / epidemiology. Deglutition Disorders / rehabilitation. Infratentorial Neoplasms / epidemiology. Lateral Medullary Syndrome / epidemiology. Risk Assessment / methods. Vagus Nerve Diseases / epidemiology. Vocal Cord Paralysis / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Causality. Comorbidity. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Outcome Assessment (Health Care) / methods. Recovery of Function / physiology. Treatment Outcome

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986724.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


54. Rosemergy I, Mossman S: Brainstem lesions presenting with nausea and vomiting. N Z Med J; 2007;120(1254):U2532
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positional vomiting is an important alerting sign for the presence of a brainstem central nervous system (CNS) lesion.
  • Failure to identify another cause of protracted vomiting should prompt consideration of a CNS cause.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Encephalomyelitis / diagnosis. Ependymoma / diagnosis. Nausea / etiology. Vomiting / etiology
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Treatment Outcome. Vertigo / etiology

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515936.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


55. David P, Sadeghi N, Neugroschel C, Jissendi P, Lubicz B, Delpierre I, Massager N, Levivier M, Balériaux D: Information on heavy equipments and facilities in Belgium: gamma-knife. JBR-BTR; 2007 Jul-Aug;90(4):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIAL: Between December 1999 and July 2007, 1620 patients were treated by GK for a large variety of indications (metastasis 26%, vascular malformations 7%, trigeminal neuralgia 14%, pituitary adenoma 3%, primary CNS tumour 8%, other tumours 6%, vestibular schwannoma 19%, meningioma 17%, functional disorders <1%).
  • [MeSH-minor] Adult. Angiography, Digital Subtraction. Astrocytoma / surgery. Belgium. Brain Diseases / surgery. Brain Neoplasms / surgery. Female. Follow-Up Studies. Humans. Intracranial Arteriovenous Malformations / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Movement Disorders / surgery. Neuroma, Acoustic / surgery. Parkinson Disease / surgery. Positron-Emission Tomography. Prolactinoma / surgery. Tomography, X-Ray Computed. Treatment Outcome. Trigeminal Neuralgia / surgery

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966240.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


56. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in resistant or relapsed pediatric solid tumors.
  • PURPOSE: We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors.
  • PATIENTS AND METHODS: Fifty two patients, median age 127.6 months, with resistant or relapsed solid tumors were enrolled.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • CONCLUSION: Oral TMZ was well tolerated in children with resistant or relapsed solid tumors and showed activity in NB and CNS tumours refractory to standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


57. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J; 2009 Feb;33(2):436-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
  • However, after an initial response, most patients will recur, particularly within the central nervous system.
  • Persistent cerebral tyrosine kinase inhibitor sensitivity should be considered in patients presenting with an early central nervous system relapse after stopping epidermal growth factor receptor tyrosine kinase inhibitor, even with a T790M-resistant mutation in noncerebral metastases.
  • Questions remain concerning the selection of sub-clones during epidermal growth factor receptor tyrosine kinase inhibitor therapy, which could differ according to metastatic sites, especially in the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Neoplasm Metastasis. Quinazolines / administration & dosage. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181917.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


58. Gerhardt CA, Vannatta K, Valerius KS, Correll J, Noll RB: Social and romantic outcomes in emerging adulthood among survivors of childhood cancer. J Adolesc Health; 2007 May;40(5):462.e9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Families were recruited when the children with cancer were 8-15-years-old and on initial treatment for a malignancy that did not primarily affect the central nervous system (i.e., non-CNS).
  • CONCLUSIONS: The social and romantic outcomes of survivors of non-CNS cancer were similar to comparison peers during the transition from adolescence to emerging adulthood.
  • [MeSH-major] Love. Neoplasms / psychology. Quality of Life. Social Adjustment. Survivors / psychology
  • [MeSH-minor] Adaptation, Physiological. Adaptation, Psychological. Adolescent. Adult. Age Factors. Case-Control Studies. Child. Female. Humans. Interpersonal Relations. Longitudinal Studies. Male. Prognosis. Reference Values. Risk Assessment. Self Concept. Sex Factors. Sickness Impact Profile. Social Behavior. Surveys and Questionnaires


59. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • PURPOSE: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


60. Pakasa NM, Pasquier B, Chambonnière ML, Morrison AL, Khaddage A, Perret AG, Dumollard JM, Barral FG, Péoc'h M: Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature. Virchows Arch; 2005 Jul;447(1):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature.
  • Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms recognized less than a decade ago.
  • Approximately 60 cases of SFT have been reported in the central nervous system.
  • We describe three atypical SFTs of the CNS, two intracranial and one within the spine.
  • The intraspinal tumor occurred at T5-T7 in a patient with multiple café-au-lait spots, was predominantly myxoid and developed a second similar lesion at S3-S5 14 years later.
  • The MiB 1 index was lower in the second tumor.
  • These atypical presentations gave us an opportunity to provide further information about the natural histological course of CNS SFTs.
  • [MeSH-major] Brain Neoplasms / pathology. Fibroma / pathology. Sella Turcica / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):808-17 [11107053.001]
  • [Cites] Virchows Arch. 2004 May;444(5):459-64 [15014990.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):213-6; discussion 216-7 [14683560.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4 Suppl Spine):358-63 [15070144.001]
  • [Cites] APMIS. 2000 Sep;108(9):617-25 [11110050.001]
  • [Cites] Histopathology. 1993 Mar;22(3):282-4 [8495961.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):217-20 [10763696.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 May;44(5):249-54 [15200060.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):69-73 [11734322.001]
  • [Cites] Pediatr Dev Pathol. 2001 May-Jun;4(3):267-75 [11370264.001]
  • [Cites] Neurosurgery. 2004 Apr;54(4):1004-9; discussion 1009 [15046670.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):490-3 [10969951.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):532-5 [10617813.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):174-8; discussion 178-9 [14751636.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):182-5 [8805158.001]
  • [Cites] Neuroradiology. 1981 Mar;21(2):55-65 [6259553.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):246-51 [15138847.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):57-69 [11763424.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):217-21 [12232579.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):160-4 [12127400.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):477-83 [9130996.001]
  • [Cites] J Neuroimaging. 2004 Jul;14(3):281-4 [15228772.001]
  • (PMID = 15926073.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


61. Kloska SP, Husstedt IW, Schlegel PM, Anneken K, Evers S, Fischbach R, Heindel W: [Magnetic resonance imaging findings of the brain in adult HIV and AIDS patients]. Rofo; 2008 Jan;180(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging findings of the brain in adult HIV and AIDS patients].
  • The spectrum of pathology affecting the central nervous system (CNS) in patients suffering from acquired immunodeficiency syndrome (AIDS) includes not only the human immunodeficiency virus (HIV) infection itself but also opportunistic infections and tumors secondary to AIDS.
  • Despite progress in antiretroviral therapy and the subsequent decrease in the incidence of associated diseases, opportunistic infections and tumors secondary to the HIV infection continue to be the limiting factor in terms of survival with AIDS.
  • Magnetic resonance imaging is often the diagnostic method of choice in suspected CNS pathology of HIV patients.
  • [MeSH-major] AIDS Dementia Complex / diagnosis. AIDS-Related Opportunistic Infections / diagnosis. Acquired Immunodeficiency Syndrome / diagnosis. Brain / pathology. Brain Neoplasms / diagnosis. HIV Infections / diagnosis. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningoencephalitis / diagnosis


62. Finsterer J, Kopsa W: Adult unilateral periventricular pseudocysts with ipsilateral headache. Clin Neurol Neurosurg; 2005 Dec;108(1):73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult unilateral periventricular pseudocysts with ipsilateral headache.
  • Since hypoxemia/ischemia, subependymal hemorrhage, CNS infection, developmental defect of the mantle layer, chromosomal disorder, Zellweger syndrome, carbon monoxide intoxication, trauma, or mitochondriopathy were not causative, the etiology of PVPC remained questionable.
  • [MeSH-major] Central Nervous System Cysts / complications. Central Nervous System Cysts / diagnosis. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / diagnosis. Headache / etiology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neurol Neurosurg. 2007 Feb;109(2):216; author reply 217 [16987593.001]
  • (PMID = 16311152.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM: Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol; 2006 Dec 20;24(36):5711-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.
  • PURPOSE: The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that could be applied to the care of patients and the design of prospective clinical trials.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology. Models, Theoretical
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4322-4; author reply 4324-5 [17878489.001]
  • (PMID = 17116938.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Falchi L, Gunnellini M, Franco L, Ferrazza P, Ascani S, Liberati AM: Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy. J Neurooncol; 2010 Mar;97(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognosis of patients suffering from secondary central nervous system (CNS) lymphoma is dismal.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Injections, Spinal. Liposomes / administration & dosage. Male. Positron-Emission Tomography / methods. Radiography. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2007 Jan;18(1):149-57 [17018708.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):685-90 [10942056.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):93-100 [15682069.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):13-21 [16173958.001]
  • [Cites] Acta Oncol. 1996;35(6):703-8 [8938217.001]
  • [Cites] Ann Hematol. 2006 Jan;85(1):45-50 [16132909.001]
  • [Cites] Onkologie. 2003 Aug;26(4):351-4 [12972702.001]
  • [Cites] Ann Hematol. 2009 Mar;88(3):193-201 [19050889.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):107-17 [17332946.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1099-107 [12176790.001]
  • [Cites] Med Pediatr Oncol. 1990;18(2):136-42 [2304422.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1762-8 [10974623.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3915-22 [17761975.001]
  • [Cites] Expert Opin Pharmacother. 2008 Feb;9(2):301-9 [18201152.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Cancer Res. 1970 Nov;30(11):2627-35 [5530557.001]
  • (PMID = 19696967.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


65. Mogler C, Kohlhof P, Penzel R, Grenacher L, Haag GM, Schirmacher P, Mueller W: A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature. Virchows Arch; 2009 Apr;454(4):475-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas generally arise in the central nervous system (CNS).
  • Careful reevaluation together with extensive review of the literature and comparison of related cases established the diagnosis after treatment failure and tumor progression.
  • The tumor was large and firm with some small cysts and showed pseudorosettes with strong glial fibrillary acidic protein (GFAP) expression.
  • In conclusion, primary extraneural ependymomas have to be included into the differential diagnosis of abdominal tumors with pseudorosette-formation, even in unusual sites, and GFAP-immunohistochemistry (IHC) supports the diagnosis.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Autonomic Pathways / pathology. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Gastrointestinal Neoplasms / pathology. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. Peripheral Nervous System Neoplasms / pathology

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant ependymoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jul;44(1):326-33 [378364.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • [Cites] Neurol India. 1969 Apr-Jun;17(2):82-4 [5823288.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):421-3 [12946033.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):764-78 [8393302.001]
  • [Cites] Am J Surg Pathol. 1982 Jun;6(4):283-92 [7114357.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):623-32 [8333561.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):56-60 [10079380.001]
  • [Cites] J Neurosurg. 1979 Sep;51(3):383-91 [469584.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):710-8 [18360284.001]
  • [Cites] J Neurooncol. 1992 Oct;14(2):135-42 [1432036.001]
  • [Cites] Medscape J Med. 2008 Feb 19;10 (2):41 [18382710.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):62-8 [3522133.001]
  • [Cites] Pathology. 2001 Feb;33(1):26-9 [11280604.001]
  • (PMID = 19238432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 15
  •  go-up   go-down


66. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group: Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2010 Jun 17;115(24):5005-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
  • The International Primary CNS Lymphoma Collaborative Group retrospectively analyzed 50 patients assembled from 12 centers in 5 countries over a 16-year period.
  • [MeSH-major] Leukemia. Leukemic Infiltration. Lymphoma, Non-Hodgkin. Nervous System Neoplasms
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Cerebrospinal Fluid / cytology. Cooperative Behavior. Female. Humans. International Cooperation. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2006 Nov;80(2):209-10 [16645712.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Intern Med. 2007;46(8):533-4 [17443052.001]
  • [Cites] Intern Med. 2007;46(13):1029-32 [17603246.001]
  • [Cites] Clin Nucl Med. 2007 Aug;32(8):646-8 [17667443.001]
  • [Cites] Clin Nucl Med. 2008 Jan;33(1):30-1 [18097253.001]
  • [Cites] J Neurol. 2008 Jan;255(1):135-7 [17994311.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):43-5 [17957824.001]
  • [Cites] Ophthalmology. 2008 May;115(5):e1-6 [18321583.001]
  • [Cites] Intern Med. 2008;47(12):1159-60 [18552480.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):77-83 [18592137.001]
  • [Cites] Muscle Nerve. 2008 Sep;38(3):1196-200 [18642385.001]
  • [Cites] Spine (Phila Pa 1976). 2008 Oct 1;33(21):E807-11 [18827688.001]
  • [Cites] Neurology. 2009 Jan 6;72(1):98 [19122040.001]
  • [Cites] Arch Dermatol. 2009 Mar;145(3):294-6 [19289760.001]
  • [Cites] J Neurosurg. 2009 Aug;111(2):247-51 [19216652.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):740-2 [11524499.001]
  • [Cites] Neurol Sci. 2000 Aug;21(4):241-5 [11214664.001]
  • [Cites] Muscle Nerve. 2001 Aug;24(8):1068-70 [11439382.001]
  • [Cites] J Peripher Nerv Syst. 2001 Dec;6(4):197-203 [11800041.001]
  • [Cites] Ann Oncol. 2002 May;13(5):802-5 [12075752.001]
  • [Cites] Ann Nucl Med. 2002 Jun;16(4):297-8 [12126101.001]
  • [Cites] Eur J Radiol. 2002 Oct;44(1):16-8 [12350404.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):104-15 [12672282.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):343-8; discussion 348 [14505860.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2403-7 [15160344.001]
  • [Cites] Eur Neurol. 2004;52(1):57-8 [15240984.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):243-4 [15332327.001]
  • [Cites] Neurology. 1989 Jan;39(1):144-6 [2535894.001]
  • [Cites] Clin Neuropathol. 1990 Sep-Oct;9(5):224-30 [2272142.001]
  • [Cites] Neurology. 2004 Nov 9;63(9):1751 [15534276.001]
  • [Cites] Eur J Haematol. 2005 Jan;74(1):66-9 [15613109.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):163-7 [15925997.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):279-80 [15980982.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1166 [16028783.001]
  • [Cites] J Neuroimaging. 2006 Apr;16(2):167-9 [16629741.001]
  • [Cites] Br J Neurosurg. 2006 Apr;20(2):103-5 [16753628.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):975-6 [16703365.001]
  • [Cites] Neurology. 2006 Aug 22;67(4):722-3 [16924037.001]
  • [Cites] J Peripher Nerv Syst. 2007 Mar;12(1):58-60 [17374105.001]
  • (PMID = 20368468.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710441
  •  go-up   go-down


67. Idowu MO, Rosenblum MK, Wei XJ, Edgar MA, Soslow RA: Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. Am J Surg Pathol; 2008 May;32(5):710-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein.
  • We reviewed the morphologic and immunohistochemical features of 5 extra-axial ependymomas occurring in adults, 1 arising in an infantile sacrococcygeal teratoma, and a control group of 10 central nervous system (CNS) ependymomas in adults.
  • The adult extra-axial cases demonstrated more architectural variability than the CNS cases.
  • We observed that both the CNS and adult extra-axial ependymomas expressed GFAP diffusely, whereas only 9 stage III, high-grade ovarian serous papillary carcinomas stained with GFAP (2 strongly and diffusely and 7 exhibiting focally weak expression).
  • There were significant immunophenotypic differences between adult extra-axial and CNS ependymomas, with extra-axial cases preferentially expressing 34betaE12 (60% vs. 0%), CK18 (100% vs. 20%), CAM 5.2 (60% vs. 10%), CK7 (80% vs. 10%), ER (100% vs. 10%), and PR (80% vs. 20%).
  • CNS ependymomas more frequently expressed CD99 (100% vs. 20%).
  • The following stains were not differentially expressed: epithelial membrane antigen (expressed in 2 of 15 cases, including both extra-axial and CNS ependymomas), synaptophysin (1/15), chromogranin (0/15), WT1 (8/15), AE1:3 (10/15), and CK20 (0/15).
  • The ependymal elements of the sacrococcygeal tumor failed to express 34betaE12, CK18, CAM 5.2, and CK7, like most CNS ependymomas.
  • The morphologic and immunophenotypic differences between extra-axial and CNS ependymomas suggest that they derive from distinct precursors and/or differentiate along distinct pathways.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / metabolism. Ependymoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunoenzyme Techniques. Infant. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360284.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


68. Sultan I, Qaddoumi I, Rodríguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M: Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer; 2010 Jan;54(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.
  • BACKGROUND: Malignant rhabdoid tumors (MRTs) are aggressive and often fatal; the Surveillance, Epidemiology, and End Results (SEER) database offers an opportunity to study this rare malignancy.
  • RESULTS: For the 229 patients included in our data, who were diagnosed from 1986 to 2005, primary tumors were located in the central nervous system (CNS) (35%), kidneys (20%), and extra-renal non-cranial sites (ERNC-MRTs) (45%).
  • Most patients with renal and CNS tumors were less than 18 years old (87% and 96%, respectively) while more than half of the patients with ERNC-MRTs (61%) were adults.
  • Among staged tumors, 23% were localized, 34% regional, and 43% distant.
  • Renal tumors had significantly more metastatic disease (47%; P = 0.006) than ERNC-MRTs.
  • Univariate and multivariate analyses showed that age at diagnosis (2-18 years), localized stage of tumors, and use of radiotherapy were significantly associated with improved survival.
  • Adults had a better outcome than young children (<2 years old) but a poorer outcome than older children (2-18 years old); tumor stage, but not radiotherapy use, affected outcome in adults.
  • CONCLUSION: Our population-based study indicates that age at diagnosis, tumor stage, and use of radiotherapy favorably impact survival rates of patients with MRTs.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult


69. Ma DK, Marchetto MC, Guo JU, Ming GL, Gage FH, Song H: Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat Neurosci; 2010 Nov;13(11):1338-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic choreographers of neurogenesis in the adult mammalian brain.
  • Neurogenesis in adults, which generates functional neural cell types from adult neural stem cells, is dynamically regulated by both intrinsic state-specific cell differentiation cues and extrinsic neural niche signals.
  • Here, we review recent evidence that epigenetic mechanisms carry out diverse roles in regulating specific aspects of adult neurogenesis and highlight the implications of such epigenetic regulation for neural plasticity and disorders.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):835-41 [16767102.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1087-93 [16810244.001]
  • [Cites] Science. 2006 Oct 6;314(5796):140-3 [17023662.001]
  • [Cites] Neuron. 2006 Oct 19;52(2):255-69 [17046689.001]
  • [Cites] Development. 2007 Jan;134(2):223-32 [17185323.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):105-13, x [17244558.001]
  • [Cites] Cell. 2007 Feb 23;128(4):635-8 [17320500.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Neurobiol Dis. 2007 Jul;27(1):77-89 [17532643.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15282-7 [17873065.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):295-7 [17936553.001]
  • [Cites] Nat Neurosci. 2007 Sep;10(9):1110-5 [17726477.001]
  • [Cites] Epigenetics. 2006 Apr-Jun;1(2):76-80 [17998809.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):415-9 [17928865.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2007 Oct;6(5):311-20 [18045159.001]
  • [Cites] Methods Cell Biol. 2008;85:243-72 [18155466.001]
  • [Cites] J Neurosci. 2008 Jan 9;28(2):395-406 [18184782.001]
  • [Cites] Cell. 2008 Feb 22;132(4):567-82 [18295576.001]
  • [Cites] Cell. 2008 Feb 22;132(4):645-60 [18295581.001]
  • [Cites] J Neurosci. 2008 Mar 5;28(10):2383-93 [18322085.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):87-99 [18371338.001]
  • [Cites] Science. 2008 Mar 28;319(5871):1785-6 [18369135.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1173-7 [18418041.001]
  • [Cites] Hum Mol Genet. 2008 Jul 1;17(13):2047-57 [18385101.001]
  • [Cites] Curr Opin Neurobiol. 2008 Feb;18(1):108-15 [18514504.001]
  • [Cites] Neuron. 2008 Aug 14;59(3):399-412 [18701066.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27644-52 [18689796.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):515-28 [18371391.001]
  • [Cites] Cell. 2008 Nov 14;135(4):738-48 [19013281.001]
  • [Cites] Neuron. 2008 Dec 10;60(5):775-87 [19081374.001]
  • [Cites] PLoS One. 2009;4(1):e4315 [19177165.001]
  • [Cites] Science. 2009 Feb 20;323(5917):1074-7 [19119186.001]
  • [Cites] Epigenetics. 2009 Jan;4(1):23-6 [19197164.001]
  • [Cites] Genes Dev. 2009 Mar 1;23(5):561-74 [19270157.001]
  • [Cites] Nat Neurosci. 2009 Apr;12(4):399-408 [19287386.001]
  • [Cites] Nature. 2009 Mar 26;458(7237):529-33 [19212323.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):361-8 [19329998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6387-92 [19332781.001]
  • [Cites] Nat Rev Genet. 2009 May;10(5):295-304 [19308066.001]
  • [Cites] Dev Biol. 2009 Apr 15;328(2):257-72 [19389366.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):188-97 [19429483.001]
  • [Cites] Cell Cycle. 2009 May 15;8(10):1526-31 [19377292.001]
  • [Cites] Science. 2009 May 15;324(5929):930-5 [19372391.001]
  • [Cites] Science. 2009 May 15;324(5929):929-30 [19372393.001]
  • [Cites] Cell Res. 2009 Jun;19(6):672-82 [19436263.001]
  • [Cites] Nature. 2009 Jul 30;460(7255):642-6 [19561591.001]
  • [Cites] Ann N Y Acad Sci. 2009 Jul;1170:664-73 [19686209.001]
  • [Cites] Nat Neurosci. 2009 Sep;12(9):1097-105 [19701198.001]
  • [Cites] Nature. 2009 Aug 27;460(7259):1127-31 [19657334.001]
  • [Cites] RNA Biol. 2009 Jul-Aug;6(3):242-7 [19305164.001]
  • [Cites] Cell. 2009 Sep 4;138(5):1019-31 [19698979.001]
  • [Cites] Hippocampus. 2009 Oct;19(10):1002-7 [19771587.001]
  • [Cites] Nature. 2009 Nov 19;462(7271):315-22 [19829295.001]
  • [Cites] Annu Rev Psychol. 2010;61:439-66, C1-3 [19958180.001]
  • [Cites] Nat Methods. 2010 Jan;7(1):47-9 [19946276.001]
  • [Cites] Stem Cells. 2010 Feb;28(2):279-86 [19882665.001]
  • [Cites] Cell Cycle. 2010 Feb 15;9(4):636-7 [20107312.001]
  • [Cites] Mol Brain. 2010;3:5 [20205849.001]
  • [Cites] Nat Neurosci. 2010 Apr;13(4):423-30 [20228804.001]
  • [Cites] J Cell Biol. 2010 Apr 5;189(1):127-41 [20368621.001]
  • [Cites] Nat Rev Neurosci. 2010 May;11(5):339-50 [20354534.001]
  • [Cites] Cell Stem Cell. 2010 May 7;6(5):433-44 [20452318.001]
  • [Cites] Neurobiol Dis. 2010 Jul;39(1):73-84 [20114075.001]
  • [Cites] J Biol Chem. 2010 Jun 18;285(25):19043-50 [20410295.001]
  • [Cites] Heredity (Edinb). 2010 Jul;105(1):122-34 [20332807.001]
  • [Cites] Stem Cells. 2010 Jun;28(6):1060-70 [20506192.001]
  • [Cites] Nucleic Acids Res. 2010 Jun;38(11):e125 [20371518.001]
  • [Cites] Nature. 2010 Aug 26;466(7310):1129-33 [20639862.001]
  • [Cites] Curr Opin Neurobiol. 2010 Aug;20(4):408-15 [20434901.001]
  • [Cites] Curr Opin Neurobiol. 2010 Aug;20(4):432-40 [20471240.001]
  • [Cites] Curr Opin Neurobiol. 2010 Aug;20(4):416-23 [20471243.001]
  • [Cites] Neuron Glia Biol. 2010 May;6(2):93-107 [20388229.001]
  • [Cites] Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):694-701 [20493980.001]
  • [Cites] Hippocampus. 2011 Feb;21(2):127-32 [20232397.001]
  • [Cites] Horm Behav. 2011 Mar;59(3):315-20 [20483357.001]
  • [Cites] Trends Cell Biol. 2000 Mar;10(3):98-105 [10675903.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] J Comp Neurol. 2001 Jul 9;435(4):406-17 [11406822.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:245-54 [12610534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6777-82 [12748381.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Science. 2003 Oct 31;302(5646):890-3 [14593184.001]
  • [Cites] Neuron. 2004 Mar 4;41(5):683-6 [15003168.001]
  • [Cites] Cell. 2004 Mar 19;116(6):779-93 [15035981.001]
  • [Cites] Curr Opin Neurobiol. 2004 Apr;14(2):186-91 [15082323.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):1013-6 [15235610.001]
  • [Cites] J Comp Neurol. 1965 Jun;124(3):319-35 [5861717.001]
  • [Cites] Biol Rev Camb Philos Soc. 1990 Nov;65(4):431-71 [2265224.001]
  • [Cites] EXS. 1993;64:452-68 [8418955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16659-64 [15537713.001]
  • [Cites] Trends Neurosci. 2005 May;28(5):219-21 [15866195.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):903-10 [15959507.001]
  • [Cites] Annu Rev Neurosci. 2005;28:223-50 [16022595.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Curr Opin Neurobiol. 2005 Oct;15(5):514-20 [16144763.001]
  • [Cites] Nat Rev Neurosci. 2006 Mar;7(3):179-93 [16495940.001]
  • (PMID = 20975758.001).
  • [ISSN] 1546-1726
  • [Journal-full-title] Nature neuroscience
  • [ISO-abbreviation] Nat. Neurosci.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD069184; United States / NIMH NIH HHS / MH / R01 MH090258-01; United States / NIMH NIH HHS / MH / R01 MH090258; United States / NIMH NIH HHS / MH / R21 MH087874; United States / NIMH NIH HHS / MH / R01 MH088485-02; United States / NIA NIH HHS / AG / R01 AG024984; United States / NIA NIH HHS / AG / AG024984; United States / NIMH NIH HHS / MH / R33 MH087874; United States / NIMH NIH HHS / MH / MH090258; United States / NINDS NIH HHS / NS / NS048271; United States / NIMH NIH HHS / MH / MH088485; United States / NINDS NIH HHS / NS / R37 NS047344; United States / NIMH NIH HHS / MH / MH087874; United States / NINDS NIH HHS / NS / R56 NS047344; United States / NINDS NIH HHS / NS / R01 NS048271; United States / NINDS NIH HHS / NS / R01 NS047344; United States / NICHD NIH HHS / HD / HD069184; United States / NINDS NIH HHS / NS / NS047344; United States / NIMH NIH HHS / MH / R01 MH088485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS367614; NLM/ PMC3324277
  •  go-up   go-down


70. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the CNS.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


71. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


72. Schmidt K, Schulz AS, Debatin KM, Friedrich W, Classen CF: CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. Pediatr Blood Cancer; 2008 Feb;50(2):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors.
  • BACKGROUND: Clinical studies analyzing CNS complications in pediatric oncology systematically are rare.
  • PROCEDURE: In a single center retrospective analysis, CNS complications in 950 subsequent pediatric patients treated between 1992 and 2004 by chemotherapy or hematopoietic stem cell transplantation (HSCT) were studied.
  • Forty-six patients had pre-existing CNS diseases and were excluded.
  • Out of the 904 remaining, 76 (8.4%) had 82 CNS complications.
  • RESULTS: The most common manifestations were seizures (in 50.6% of the CNS episodes), altered states of consciousness, and motor deficits (in 47.5% of the episodes each).
  • CNS complications were caused by infections (26.8%), toxicity (25.6%), neoplasma (13.4%), vascular (10.9%), and metabolic disturbances (8.5%).
  • Patients (23.7%) died from the CNS event.
  • CONCLUSIONS: These data show that there is not one typical CNS complication, but a wide variety.
  • [MeSH-major] Central Nervous System Diseases / etiology. Hematologic Diseases / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17455315.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol; 2010 Mar;119(3):317-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.
  • Primary melanocytic neoplasms of the central nervous system (CNS) are uncommon neoplasms derived from melanocytes that normally can be found in the leptomeninges.
  • Characteristic genetic alterations in this group of neoplasms have not yet been identified.
  • Using direct sequencing, we investigated 19 primary melanocytic lesions of the CNS (12 melanocytomas, 3 intermediate-grade melanocytomas, and 4 melanomas) for hotspot oncogenic mutations commonly found in melanocytic tumors of the skin (BRAF, NRAS, and HRAS genes) and uvea (GNAQ gene).
  • Somatic mutations in the GNAQ gene at codon 209, resulting in constitutive activation of GNAQ, were detected in 7/19 (37%) tumors, including 6/12 melanocytomas, 0/3 intermediate-grade melanocytomas, and 1/4 melanomas.
  • These GNAQ-mutated tumors were predominantly located around the spinal cord (6/7).
  • One melanoma carried a BRAF point mutation that is frequently found in cutaneous melanomas (c.1799 T>A, p.V600E), raising the question whether this is a metastatic rather than a primary tumor.
  • We conclude that somatic mutations in the GNAQ gene at codon 209 are a frequent event in primary melanocytic neoplasms of the CNS.
  • This finding provides new insight in the pathogenesis of these lesions and suggests that GNAQ-dependent mitogen-activated kinase signaling is a promising therapeutic target in these tumors.
  • The prognostic and predictive value of GNAQ mutations in primary melanocytic lesions of the CNS needs to be determined in future studies.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. GTP-Binding Protein alpha Subunits / genetics. Melanocytes / pathology. Melanoma / pathology. Mutation / genetics
  • [MeSH-minor] Adult. Aged. Codon / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, ras / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Retrospective Studies. Tissue Fixation

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2290-1 [19349541.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):813-5 [19654573.001]
  • [Cites] PLoS One. 2009;4(8):e6833 [19718445.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):496-501 [10591209.001]
  • [Cites] Annu Rev Biochem. 2000;69:795-827 [10966476.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3468-74 [12429636.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5761-6 [14522897.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1160-2 [14708620.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):705-10 [15252839.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):961-8 [15322542.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):935-6 [15340429.001]
  • [Cites] Neurosurgery. 1981 Jan;8(1):26-30 [7207769.001]
  • [Cites] J Invest Dermatol. 1984 Mar;82(3):235-8 [6699426.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):948 [3572529.001]
  • [Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]
  • [Cites] Cancer. 1988 May 1;61(9):1926-34 [3355984.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):747-55 [1869648.001]
  • [Cites] Neurology. 1993 Feb;43(2):381-6 [8437707.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1895-901 [8266082.001]
  • [Cites] Neurosurgery. 1994 Mar;34(3):533-7; discussion 637 [8190231.001]
  • [Cites] Pathologica. 1997 Apr;89(2):168-74 [9411364.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]
  • [Cites] Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315 [15618991.001]
  • [Cites] Melanoma Res. 2006 Apr;16(2):97-103 [16567964.001]
  • [Cites] Melanoma Res. 2006 Aug;16(4):267-73 [16845322.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):578-88 [17295241.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):183-9 [18300768.001]
  • [Cites] J Neurosurg Spine. 2008 Jul;9(1):48-54 [18590410.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • (PMID = 19936769.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


74. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE: Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer; 2007 Sep 15;110(6):1329-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors performed a retrospective analysis to determine whether the treatment of metastatic melanoma with biochemotherapy would result in similar outcomes if brain metastases were first controlled with aggressive, central nervous system (CNS)-directed treatment.
  • RESULTS: Median survival from the time of the diagnosis of metastatic melanoma was 15.8 months for patients with brain metastases and 11.1 months for those without CNS involvement (P = .26 by the log-rank test; P = .075 by the Gehan Wilcoxon test).
  • Dacarbazine-based and temozolomide-based regimens appeared similar with regard to their effect on overall survival and CNS disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Melanoma / secondary. Melanoma / therapy. Radiosurgery
  • [MeSH-minor] Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Male. Middle Aged. Patient Care Team. Recombinant Proteins. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17623835.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


75. Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS: When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol; 2010 May;21(5):1058-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?
  • BACKGROUND: The incidence and risk factors of central nervous system (CNS) invasion is still unclear in extranodal natural killer (NK)/T-cell lymphoma, nasal type.
  • PATIENTS AND METHODS: We analyzed 208 patients to study the clinical features and outcomes of CNS disease in extranodal NK/T-cell lymphoma.
  • RESULTS: Twelve patients (5.76%, 12/208) experienced CNS disease during treatment or follow-up period (median 11.62 months, range 0.2-123.2 months).
  • The clinical variables associated with CNS disease were Ann Arbor stage III/IV (15.87%, P <0.001), regional lymph node involvement (10.41%, P = 0.006), group III/IV of NK/T-cell lymphoma prognostic index (NKPI; 10.20%, P = 0.003), high/high-intermediate international prognostic index (9.30%, P = 0.072) and extra-upper aerodigestive primary sites (9.75%, P = 0.008).
  • In multivariate analysis, NKPI retained the strongest statistical power to predict CNS disease (P = 0.007, relative risk 9.289, 95% confidence interval 1.828-47.212) in extranodal NK/T-cell lymphoma.
  • CONCLUSIONS: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence.
  • Nevertheless, CNS prophylaxis should be considered in NKPI groups III and IV.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850636.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Okita R, Saeki T, Takashima S, Aogi K, Ohsumi S: Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer. Hiroshima J Med Sci; 2005 Mar;54(1):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive central nervous system metastases in responder patients for outside central nervous system metastases on trastuzumab-based therapy--report of two cases of refractory breast cancer.
  • We report two cases of central nervous system (CNS) metastases during systemic response to trastuzumab in combination with chemotherapy for refractory breast cancer.
  • A follow-up computed tomography scan revealed that their diseases continued to respond outside the CNS.
  • These cases suggest that the failure of trastuzumab to cross the blood-brain barrier may compromise its overall effectiveness and raises the possibility that CNS metastasis may become clinically more significant in patients receiving antibody-based therapies, including patients responding to therapy outside the CNS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Breast Neoplasms / therapy. Cerebellar Neoplasms / secondary
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier. Combined Modality Therapy. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Radiosurgery. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847063.001).
  • [ISSN] 0018-2052
  • [Journal-full-title] Hiroshima journal of medical sciences
  • [ISO-abbreviation] Hiroshima J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  •  go-up   go-down


77. Lackner P, Guengoer E, Beer R, Broessner G, Helbok R, Deisenhammer F, Schmutzhard E, Pfausler B: IgG-index predicts neurological morbidity in patients with infectious central nervous system diseases. BMC Infect Dis; 2010;10:202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgG-index predicts neurological morbidity in patients with infectious central nervous system diseases.
  • BACKGROUND: Prognosis assessment of patients with infectious and neoplastic disorders of the central nervous system (CNS) may still pose a challenge.
  • RESULTS: In the initial spinal tap, the IgG-index was the only independent predictor for unfavorable outcome (GOS < 5) in patients with infectious CNS diseases but not in patients with leptomeningeal metastases.
  • CONCLUSION: The present study suggests that in infectious CNS diseases an elevated IgG-Index might be an additional marker for the early identification of patients at risk for neurological morbidity.
  • [MeSH-major] Immunoglobulin G / cerebrospinal fluid. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningitis, Bacterial / diagnosis. Meningoencephalitis / diagnosis
  • [MeSH-minor] Adult. Aged. Cerebrospinal Fluid / chemistry. Cerebrospinal Fluid / cytology. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2000 Apr;28(4):1027-32 [10809277.001]
  • [Cites] Lancet Neurol. 2010 Mar;9(3):254-63 [20138011.001]
  • [Cites] J Neurol Sci. 2001 Mar 1;184(2):101-22 [11239944.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1727-33 [11742046.001]
  • [Cites] J Neuroimmunol. 2002 Jan;122(1-2):106-16 [11777549.001]
  • [Cites] Trends Neurosci. 2002 Jan;25(1):38-45 [11801337.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):352-8 [12140104.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1549-56 [12432041.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1015-25 [12690042.001]
  • [Cites] Int J Med Microbiol. 2003 Aug;293(4):241-9 [14503789.001]
  • [Cites] Intensive Care Med. 2003 Nov;29(11):1967-73 [12904848.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1267-84 [15494903.001]
  • [Cites] J Infect. 1985 Mar;10(2):143-57 [4008963.001]
  • [Cites] Br J Biomed Sci. 1998 Dec;55(4):253-7 [10436540.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):75-80 [16401850.001]
  • [Cites] Eur J Neurol. 2006 Sep;13(9):913-22 [16930354.001]
  • [Cites] J Neuroimmunol. 2007 Mar;184(1-2):45-52 [17210186.001]
  • [Cites] J Neuroimmunol. 2007 Jul;187(1-2):139-46 [17512988.001]
  • [Cites] Ann Neurol. 2008 Jan;63(1):90-7 [17823938.001]
  • [Cites] Infection. 1999;27(4-5):239-43 [10885833.001]
  • (PMID = 20618966.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G
  • [Other-IDs] NLM/ PMC2912906
  •  go-up   go-down


78. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood; 2005 Feb 1;105(3):948-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
  • In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h).
  • Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate tumor mass MTX can be reduced from 5 g/m(2) to 1 g/m(2).
  • Patients received 2 5-day therapy courses in risk group R1 (resected), 4 in R2 (lactate dehydrogenase [LDH] < 500 U/L), 5 in R3 (LDH > 500 to < 1000 U/L) and 6 in R4 (LDH > 1000 U/L and/or central nervous system [CNS] disease).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Survival Analysis. Time Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486066.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R: Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma; 2007 Jun;48(6):1119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
  • We report the efficacy of salvage therapy with a modified ProMACE-MOPP combined with radiation in patients with primary central nervous system lymphoma (PCNSL).
  • Nine patients with CNS relapse were retreated with additional cycles of the ProMACE-MOPP hybrid regimen with a 90% objective response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Methotrexate / adverse effects. Methotrexate / therapeutic use. Middle Aged. Neurotoxicity Syndromes / drug therapy. Neurotoxicity Syndromes / radiotherapy. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Retrospective Studies. Survival Analysis. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577775.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


80. Hambardzumyan D, Becher OJ, Holland EC: Cancer stem cells and survival pathways. Cell Cycle; 2008 May 15;7(10):1371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas and medulloblastomas are the most frequent malignant brain tumors in adult and children respectively.
  • Although both tumors arise in the CNS, there is a significant difference in their therapeutic response.
  • During the last decade several reports have demonstrated the existence of cancer stem cells in brain tumors, their location and their response to treatment.
  • We have recently described the therapeutic response of medulloblastomas to radiation in their native microenvironment, illustrating how p53 and Pi3K signaling pathways lead to the evasion of cell death by the nestin-expressing cells in the perivascular stem cell niche, even while the bulk of tumor succumbs to apoptosis.(1) It remains to be determined whether this mechanism of tumor resistance applies to the more complex stem-cell niche and tumor bulk of gliomas.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Medulloblastoma / radiotherapy. Neoplastic Stem Cells / radiation effects. Signal Transduction / radiation effects
  • [MeSH-minor] Animals. Humans. Intermediate Filament Proteins / metabolism. Mice. Models, Biological. Nerve Tissue Proteins / metabolism. Nestin. Phosphatidylinositol 3-Kinases / metabolism. Receptors, Notch / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421251.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 5R01CA100688-2; United States / NCI NIH HHS / CA / R01CA 5R01CA099489-1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Notch; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Number-of-references] 112
  •  go-up   go-down


81. Gerhardt CA, Dixon M, Miller K, Vannatta K, Valerius KS, Correll J, Noll RB: Educational and occupational outcomes among survivors of childhood cancer during the transition to emerging adulthood. J Dev Behav Pediatr; 2007 Dec;28(6):448-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Families were recruited when children with cancer were 8 to 15 years old and receiving initial treatment for a malignancy that did not primarily affect the central nervous system (CNS).
  • [MeSH-major] Career Choice. Educational Status. Employment. Leukemia / rehabilitation. Lymphoma / rehabilitation. Neoplasms / rehabilitation. Rehabilitation, Vocational. Survivors / psychology
  • [MeSH-minor] Absenteeism. Adolescent. Adult. Female. Humans. Learning Disorders / psychology. Learning Disorders / rehabilitation. Longitudinal Studies. Male. Peer Group. Personality Assessment. Reference Values. Self Concept. Sex Factors. Wechsler Scales


82. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • He presented with intratumoral hemorrhage and he underwent radical resection of tumor in 2003.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Current diagnostic methods of oligodendroglial tumors are discussed in context of differentiating oligodendrogliomas from other clear cell neoplasms of CNS, especially from extraventricular neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


83. Yoshimi A, Taoka K, Nakasone H, Iijima K, Kida M, Iki S, Urabe A, Usuki K: [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]. Rinsho Ketsueki; 2006 Dec;47(12):1533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Superior sagittal sinus thrombosis (SSST) has been reported to be caused by coagulopathy following oral contraceptive therapy, DIC, infection around the sinus, compression from a tumor, infiltration of tumor, and an inherited deficiency of proteins C and S, but SSST associated with hematological malignancies and L-asparaginase (L-Asp) therapy is rare.
  • We report a case of an adult patient with acute lymphoblastic leukemia (ALL) who developed SSST during the remission induction therapy.
  • A 25-year-old man was admitted with left facial nerve palsy and, following bone marrow aspiration and lumbar puncture, he was diagnosed as having T-ALL with CNS involvement.
  • Lymphoid malignancy (ALL in particular), the use of L-Asp, CNS involvement, and intrathecal chemotherapy might be risk factors for the occurrence SSST.
  • When a patient with those factors develops any neurological symptoms, we should pay attention to the occurrence of SSST, as well as stroke or CNS involvement, though SSST is rare.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / administration & dosage. Asparaginase / adverse effects. Central Nervous System Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sagittal Sinus Thrombosis / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Facial Paralysis / etiology. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Remission Induction. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233472.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E: Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2008 Feb 1;111(3):1085-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.
  • Isolated central nervous system (CNS) relapse involving the brain parenchyma is a rare complication of systemic non-Hodgkin lymphoma.
  • After complete response to initial non-Hodgkin lymphoma treatment, patients with isolated CNS relapse with the brain parenchyma as initial relapse site were eligible.
  • Patients with isolated CNS relapse involving only the cerebrospinal fluid were not eligible.
  • Brain relapse was identified by neuroimaging in all patients; in 54 (48%), diagnostic brain tumor specimen was obtained.
  • Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma.
  • [MeSH-major] Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cerebral Hemorrhage. Female. Humans. Male. Middle Aged. Recurrence


85. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK: A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol; 2008 Apr;10(2):208-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of intraventricular (IVent) topotecan in patients with neoplastic meningitis (NM), we conducted a phase II, open-label, nonrandomized, single-arm trial of IVent topotecan in patients with NM using 400 mug of topotecan IVent twice weekly for 6 weeks, followed by evaluation with imaging, cerebrospinal fluid (CSF), and physical examinations.
  • Primary cancers included breast (19), lung (13), CNS (14), and others (16).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Injections, Spinal. Male. Middle Aged. Prognosis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Neurology. 2004 Dec 14;63(11):2159-61 [15596770.001]
  • [Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):143-7 [12506183.001]
  • [Cites] Drugs Exp Clin Res. 1986;12(1-3):43-50 [3732054.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(3):213-7 [3663957.001]
  • [Cites] J Neurooncol. 1987;5(4):315-22 [3126273.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1685-95 [2001559.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20 [1331485.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31(3):229-39 [1464161.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):561-9 [8445432.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Br J Cancer. 1997;76(2):211-9 [9231921.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):157-63 [11161370.001]
  • (PMID = 18316473.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC2613823
  •  go-up   go-down


86. Park JH, Park EC, Park JH, Kim SG, Lee SY: Job loss and re-employment of cancer patients in Korean employees: a nationwide retrospective cohort study. J Clin Oncol; 2008 Mar 10;26(8):1302-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female sex, younger age and older age, company employee, lower income, blood cancer, and brain and CNS, lung, and liver cancer were significant predictors of early job loss or delayed re-employment.
  • [MeSH-major] Asian Continental Ancestry Group / psychology. Employment / psychology. Neoplasms / psychology. Unemployment / psychology
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323554.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS: Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience; 2007 Jul 29;147(4):928-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are adrenal medullary tumors that typically occur in adult patients, with increased frequency in multiple endocrine neoplasia type 2, von Hippel-Lindau disease, familial paraganglioma syndromes and neurofibromatosis type 1 (NF1).
  • Pheochromocytomas arise in adult mice with a heterozygous knockout mutation of exon 31 of the murine Nf1 gene, providing a mouse model for pheochromocytoma development in NF1.
  • We performed a microarray-based gene expression profiling study comparing mouse pheochromocytoma tissue to normal adult mouse adrenal medulla to develop a basis for studying the pathobiology of these tumors.
  • The findings demonstrate that pheochromocytomas from adult neurofibromatosis knockout mice express multiple developmentally regulated genes involved in early development of both the CNS and peripheral nervous system.
  • One of the most highly overexpressed genes is receptor tyrosine kinase Ret, which is known to be transiently expressed in the developing adrenal gland, down-regulated in adult adrenals and often overexpressed in human pheochromocytomas.
  • The findings are consistent with the recently proposed concept that persistent neural progenitors might give rise to pheochromocytomas in adult mouse adrenals and suggest that events predisposing to tumor development might occur before formation of the adrenal medulla or migration of cells from the neural crest.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Neurofibromin 1 / deficiency. Pheochromocytoma / genetics. Proto-Oncogene Proteins c-ret / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582688.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 46588; United States / NINDS NIH HHS / NS / NS 36785
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Ret protein, mouse
  •  go-up   go-down


88. Zou P, Mulhern RK, Butler RW, Li CS, Langston JW, Ogg RJ: BOLD responses to visual stimulation in survivors of childhood cancer. Neuroimage; 2005 Jan 1;24(1):61-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children surviving certain cancers have a high incidence of cognitive deficits caused by central nervous system (CNS) disease or treatments directed at the CNS.
  • The activation was normally located in the primary visual cortex in 13 survivors, but the activation volume was significantly smaller in brain tumor survivors than in other groups.
  • [MeSH-major] Brain Damage, Chronic / diagnosis. Brain Neoplasms / therapy. Cerebral Cortex / physiopathology. Cognition Disorders / diagnosis. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Oxygen / blood. Pattern Recognition, Visual / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Arousal / physiology. Attention / physiology. Child. Child, Preschool. Dominance, Cerebral / physiology. Energy Metabolism / physiology. Feasibility Studies. Fourier Analysis. Humans. Oxygen Consumption / physiology. Photic Stimulation. Psychomotor Performance / physiology. Reference Values. Risk Assessment. Temporal Lobe / physiology


89. Snoei J, Urbach H, Engels G, Fassunke J, von Lehe M, Becker AJ, Majores M: Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread. Neuropathology; 2009 Apr;29(2):116-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of protein-o-mannosyltransferase-1 in glioneuronal and glial brain tumors with subarachnoid spread.
  • Hypothesizing it as analogous in gliomas, we have performed a comprehensive polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis of the POMT1 gene in 41 brain tumor specimens.
  • Each specimen was subjected to laser capture microdissection analyses to dissect: (i) subarachnoid tumor components;.
  • (ii) deeply localized tumor areas; and (iii) histologically unaffected CNS fragments.
  • Exon 7 bore two sequence alterations, one 751C > T transition with amino acid exchange of arginine by tryptophane (Arg251Trp) (n = 12/41 in Tu vs n = 7/82 in Co) and a 752G > A transition with replacement of arginine by glutamine (Arg251Gln) (n = 3/41 in Tu vs n = 0/82 in Co) that were significantly increased in the tumor specimens compared to controls (P < 0.05).
  • We conclude that a significant increase of POMT1 missense mutations may indicate a functional role in neoplastic conditions in individual tumors.
  • Future studies will be important to evaluate a functional impact of POMT1 alterations in human brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Mannosyltransferases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Microdissection. Middle Aged. Mutation, Missense. Polymerase Chain Reaction. Polymorphism, Genetic. Sequence Analysis, DNA. Subarachnoid Space. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647264.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.4.1.- / Mannosyltransferases; EC 2.4.1.109 / protein O-mannosyltransferase
  •  go-up   go-down


90. Wiedemeyer K, Hartschuh W: Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas. J Dtsch Dermatol Ges; 2009 Jul;7(7):612-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It represents a rare congenital nevus syndrome with alterations of skin, bones, CNS, eyes and heart.
  • Nevi sebacei can proliferate and develop into epithelial tumors like trichoblastoma, syringocystadenoma and basal cell carcinoma.
  • We present an adult woman with SFMS who was followed by multiple specialties since birth without the correct diagnosis being made.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Merkel Cells / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192012.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG: Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol; 2005 Dec 20;23(36):9172-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia.
  • PURPOSE: CNS relapse of pediatric acute myeloid leukemia (AML) is an infrequent occurrence.
  • This review examines the risk factors and therapy used for patients with an isolated CNS relapse.
  • PATIENTS AND METHODS: Records of 886 patients with de novo AML were reviewed, and patients who entered remission at the end of one course of therapy and developed an isolated CNS relapse as their first event were analyzed (n = 690).
  • RESULTS: Thirty-three patients developed an isolated CNS relapse.
  • Factors at diagnosis significantly associated with an isolated CNS relapse, compared with no CNS relapse, included age 0 to 2 years (70% v 27%, respectively; P < .001), enlarged liver (79% v 39%, respectively; P < .001) or spleen (79% v 39%, respectively; P < .001) at diagnosis, CNS disease at diagnosis (33% v 9%, respectively; P < .001), median WBC count (79.2 v 19.3 x 10(3) microL, respectively; P < .001), French-American-British M5 morphology (45% v 15%, respectively; P < .001), and chromosome 11 abnormalities (44% v 18%, respectively; P = .022).
  • Treatment of the isolated CNS relapse varied from local therapy with intrathecal chemotherapy and/or radiation therapy to systemic therapy with chemotherapy with or without bone marrow transplantation.
  • The 8-year overall survival for patients after an isolated CNS relapse was similar to patients after a bone marrow relapse (26% +/- 16% v 21% +/- 5%, respectively).
  • CONCLUSION: Significant predictors for isolated CNS relapse were identified.
  • This study demonstrated that there may be no benefit to systemic therapy versus CNS-directed therapy in outcome.
  • The data support CNS-directed therapy to treat isolated CNS relapse.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Prognosis. Recurrence. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361619.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res; 2009 Feb 15;15(4):1452-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge.
  • Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial.
  • The current study was done to further evaluate the CNS activity of lapatinib.
  • The primary end point was CNS objective response, defined as >or=50% volumetric reduction of CNS lesion(s) in the absence of increasing steroid use, progressive neurologic signs and symptoms, or progressive extra-CNS disease.
  • CNS objective responses to lapatinib were observed in 6% of patients.
  • In an exploratory analysis, 21% of patients experienced a >or=20% volumetric reduction in their CNS lesions.
  • Of the 50 evaluable patients who entered the lapatinib plus capecitabine extension, 20% experienced a CNS objective response and 40% experienced a >or=20% volumetric reduction in their CNS lesions.
  • CONCLUSIONS: This study confirms the modest CNS antitumor activity of lapatinib.
  • Further studies of lapatinib-based regimens for CNS metastases from HER2+ breast cancer are warranted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Middle Aged. Prospective Studies


93. Back MF, Baggarley S, Park E, Wei R: Optimising radiation therapy techniques for tumours of the central nervous system. Ann Acad Med Singapore; 2007 May;36(5):332-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimising radiation therapy techniques for tumours of the central nervous system.
  • INTRODUCTION: This study aims to assess the early tumour outcome and morbidity associated with radiation therapy (RT) in tumours of the central nervous system (CNS).
  • Tumour types were categorised into glioma, base of skull, pituitary, germ cell or primitive neuroectodermal tumour (PNET) and other malignant CNS tumours.
  • RESULTS: One hundred and fifty-two patients with CNS tumours were managed with radical intent over the 4-year period.
  • CONCLUSIONS: RT for CNS tumours using modern techniques was well-tolerated with good tumour outcome and minimal morbidity.
  • [MeSH-major] Central Nervous System / physiopathology. Central Nervous System Neoplasms / radiotherapy. Radiotherapy / methods. Radiotherapy / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prospective Studies. Singapore. Survival Analysis

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549279.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


94. Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA: Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res; 2009 May 1;69(9):3795-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have analyzed the DNA copy numbers for over 100,000 single-nucleotide polymorphism loci across the human genome in genomic DNA from 313 lymph node-negative primary breast tumors for which genome-wide gene expression data were also available.
  • In the training set of 200 patients, we constructed an 81-gene prognostic copy number signature (CNS) that identified a subgroup of patients with increased probability of distant metastasis in the independent validation set of 113 patients [hazard ratio (HR), 2.8; 95% confidence interval (95% CI), 1.4-5.6] and in an external data set of 116 patients (HR, 3.7; 95% CI, 1.3-10.6).
  • This very poor prognostic group identified by CNS and GES was putatively more resistant to preoperative paclitaxel and 5-fluorouracil-doxorubicin-cyclophosphamide combination chemotherapy (P = 0.0048), particularly against the doxorubicin compound, while potentially benefiting from etoposide.
  • When combined with gene expression-based signatures for prognosis, the CNS refines risk classification and can help identify those breast cancer patients who have a significantly worse outlook in prognosis and a potential differential response to chemotherapeutic drugs.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Gene Dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Middle Aged. Neoplasm Metastasis. Polymorphism, Single Nucleotide. Receptors, Estrogen / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336569.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


95. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE: Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol; 2008 Mar;39(3):410-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor.
  • Inflammatory myofibroblastic tumor (IMT) is a distinctive spindle cell lesion and occurs primarily in soft tissue.
  • IMT in the central nervous system (CNS) is rare, its characteristics are poorly defined, and its relation to similar tumors at other sites is unclear.
  • To better characterize IMT within the CNS, we studied clinicopathologic features of 6 IMTs and compared them with 18 nonneoplastic lesions originally classified as IP.
  • All tumors were composed of neoplastic spindle cells and a variable amount of inflammatory infiltrate.
  • We suggest that IMT in the CNS is distinct from the nonneoplastic IP, and distinguishing IMT from nonneoplastic lesions should enable better decisions for patient management.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Granuloma, Plasma Cell / classification. Granuloma, Plasma Cell / pathology. Myofibroma / classification. Myofibroma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261625.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. al Barbarawi M, Smith SF, Qudsieh S, Sekhon LH: Multiple cerebral and leptomeningeal metastases from ovarian carcinoma: unusual early presentation. J Clin Neurosci; 2005 Aug;12(6):697-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike primary tumours such as malignant melanoma, ovarian carcinoma does not have a predilection for the central nervous system (CNS), but the rare instances with CNS involvement occur at an advanced stage of the disease.
  • Once the CNS is involved, the outcome is abysmal, even with multimodality therapy.
  • It is extremely unusual for ovarian carcinoma to present with multiple CNS involvement.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / pathology. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy / methods. Female. Humans. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115553.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


97. Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, Warmuth-Metz M, Kortmann RD, Pietsch T, Wolff JE: Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer; 2006 Oct 23;95(8):991-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SDD was located parenchymal in the supratentorial (34.8%), infratentorial (6.5%), supratentorial and infratentorial (19.6%), spinal (10.9%), spinal and cerebral (6.5%) regions of the CNS, or leptomeningeal (21.7%).
  • [MeSH-major] Brain Neoplasms / pathology. Brain Stem Neoplasms / pathology. Glioma / pathology. Pons
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / secondary. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / analogs & derivatives. Etoposide / administration & dosage. Female. Glioblastoma / diagnosis. Glioblastoma / secondary. Humans. Infant. Kaplan-Meier Estimate. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Radiotherapy. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):677-80 [9486619.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):179-83 [15925999.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2583-7 [16080497.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):945-9 [12434281.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):227-35 [12675316.001]
  • [Cites] J Neurooncol. 2003 Jun;63(2):191-9 [12825824.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1750-7 [15073866.001]
  • [Cites] Ann Neurol. 1985 Aug;18(2):217-21 [4037762.001]
  • [Cites] Neurosurgery. 1986 Aug;19(2):247-51 [3748352.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):355-64 [2823687.001]
  • [Cites] Ann Neurol. 1990 Feb;27(2):167-73 [2317012.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):64-71 [1738457.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1414-21 [8339232.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):281-7 [16598416.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • (PMID = 17047647.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide
  • [Other-IDs] NLM/ PMC2360717
  •  go-up   go-down


98. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, Yasui Y, Robison LL, Neglia JP: Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood; 2008 Jun 15;111(12):5515-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent ALL (n = 483) and second neoplasms (SNs; n = 89) were the major causes of death.
  • Among 185 survivors, 199 SNs occurred, 53% in the CNS.